,Rank,NCTId,Condition,BriefTitle,InterventionName,OfficialTitle,LocationCity,LocationState,LocationCountry,StartDate
0,1,NCT02213705,SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT,Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells,INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS,Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells,Paris,,France,"May 6, 2014"
1,2,NCT01770613,ST Segment Elevation Myocardial Infarction (STEMI)|Allogeneic Mesenchymal Bone Marrow Cells,A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI),Stem cells,"A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)",Gilbert|Atlanta,Arizona|Georgia,United States|United States,February 2013
2,3,NCT00953485,Sjogren's Syndrome|Mesenchymal Stem Cells,Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS),Allogeneic Mesenchymal Stem Cells (AlloMSC),Clinical Trial of Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome - Phase Ⅰ/Ⅱ,Nanjing,Jiangsu,China,June 2009
3,4,NCT03925324,Ischemic Heart Disease|Non-ischemic Cardiomyopathy,Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device,Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Placebo,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device",Washington,District of Columbia,United States,"May 3, 2019"
4,5,NCT01771679,Chronic Effect of Ultraviolet Radiation on Photoaged Skin|Dermatologic Disorders,Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging,Allogeneic Mesenchymal Bone Marrow Cells,"A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging",La Mesa|San Diego,California|California,United States|United States,July 2015
5,6,NCT03042572,Peripheral Arterial Disease|Cardiovascular Diseases|Vascular Diseases,Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs,Allogeneic Mesenchymal Stromal Cell|Placebo,"Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial",Utrecht,,Netherlands,December 2018
6,7,NCT04776239,Diabetes Mellitus|Ischemic Heart Disease,Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD),100 million Allogeneic Mesenchymal Human Stem Cells|Placebo,Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease.,Miami,Florida,United States,"August 16, 2021"
7,8,NCT01378182,Wilson's Disease,Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis,allogeneic mesenchymal stem cell transplantation,Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis,Ankara,,Turkey,April 2011
8,9,NCT00555828,Myocardial Infarction,Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction,Allogeneic Mesenchymal Precursor Cells (MPCs)|Standard-of-care treatment with NOGA® mapping and staged injections.|Allogeneic Mesenchymal Precursor Cells (MPCs)|Standard-of-care treatment with NOGA® mapping and staged injections.|Allogeneic Mesenchymal Precursor Cells (MPCs)|Standard-of-care treatment with NOGA® mapping and staged injections.,A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction,Minneapolis|Houston,Minnesota|Texas,United States|United States,March 2008
9,10,NCT02032004,Chronic Heart Failure,Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.,Allogeneic Mesenchymal Precursor Cells (MPCs)|Sham Comparator,"Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1",Birmingham|Birmingham|Gilbert|Mesa|Phoenix|Tucson|La Jolla|La Jolla|Los Angeles|Los Angeles|Orange|Oxnard|Stanford|Boynton Beach|Clearwater|Gainesville|Jacksonville|Miami|Orlando|Tampa|Atlanta|Augusta|Chicago|Iowa City|Lexington|Louisville|New Orleans|Boston|Saginaw|Minneapolis|Rochester|Las Vegas|Newark|New York|Charlotte|Durham|Cincinnati|Cincinnati|Cleveland|Columbus|Allentown|Philadelphia|Philadelphia|Philadelphia|Pittsburgh|Germantown|Austin|Dallas|Houston|Houston|Salt Lake City|Seattle|Madison|Milwaukee|Milwaukee|Wausau|Edmonton|Victoria|Toronto,Alabama|Alabama|Arizona|Arizona|Arizona|Arizona|California|California|California|California|California|California|California|Florida|Florida|Florida|Florida|Florida|Florida|Florida|Georgia|Georgia|Illinois|Iowa|Kentucky|Kentucky|Louisiana|Massachusetts|Michigan|Minnesota|Minnesota|Nevada|New Jersey|New York|North Carolina|North Carolina|Ohio|Ohio|Ohio|Ohio|Pennsylvania|Pennsylvania|Pennsylvania|Pennsylvania|Pennsylvania|Tennessee|Texas|Texas|Texas|Texas|Utah|Washington|Wisconsin|Wisconsin|Wisconsin|Wisconsin|Alberta|British Columbia|Ontario,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada,"February 14, 2014"
10,11,NCT02886884,"Diabetes Mellitus, Type 2",Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,20 million Allogeneic Mesenchymal Human Stem Cells|100 million Allogeneic Mesenchymal Human Stem Cells,"A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects",Miami,Florida,United States,"October 20, 2017"
11,12,NCT04366271,COVID,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Mesenchymal cells|Standard of care,Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19,Getafe|Barakaldo|Madrid|Madrid|Madrid|Madrid,Madrid,Spain|Spain|Spain|Spain|Spain|Spain,"May 7, 2020"
12,13,NCT03874572,Xerostomia Due to Radiotherapy|Hyposalivation|Xerostomia|Oropharynx Cancer|Salivary Gland Diseases|Dry Mouth|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Stem Cells,Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth,Allogeneic adipose derived stem/stromal cells,A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia in Previous Oropharynx Cancer Patients,Copenhagen|Copenhagen,,Denmark|Denmark,"March 18, 2019"
13,14,NCT00962923,Systemic Sclerosis|Mesenchymal Stem Cells,Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc),Allogeneic Mesenchymal Stem Cells (AlloMSC),,Nanjing,Jiangsu,China,August 2009
14,15,NCT04626583,Mesenchymal Stromal Cells|Cornea|Safety|Corneal Defect,Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells,Allogeneic MSC,Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells for Promoting Corneal Repair,Chicago,Illinois,United States,"March 5, 2021"
15,16,NCT01851070,Rheumatoid Arthritis,A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor,Allogeneic Mesenchymal Precursor Cells|Normal Saline,"A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor",Anniston|Gilbert|El Cajon|Los Angeles|Upland|Ocala|Palm Harbor|Sarasota|Tampa|Baltimore|Frederick|Worcester|Rochester|Fair Lawn|Charlotte|Oklahoma City|Pittsburgh|Jackson|Houston|San Antonio|Camperdown|Hobart|Malvern,Alabama|Arizona|California|California|California|Florida|Florida|Florida|Florida|Maryland|Maryland|Massachusetts|Minnesota|New Jersey|North Carolina|Oklahoma|Pennsylvania|Tennessee|Texas|Texas|New South Wales|Tasmania|Victoria,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia,July 2013
16,17,NCT04385056,Bradykinesia,Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia,MSCTC-0010,"An Open-label, Dose-escalation Study to Evaluate the Use of Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells (UC-MSCs) for the Treatment of Bradykinesia",Paducah|Chesterfield|Brentwood,Kentucky|Missouri|Tennessee,United States|United States|United States,"December 15, 2020"
17,18,NCT01759212,Heart Failure|Ischemic Cardiomyopathy,Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.,Allogeneic stem cells implantation,Safety and Efficacy of Intramyocardial Implantation of Allogeneic Mesenchymal Stem Cells in Patients With End-stage Heart Failure Undergoing Left Ventricular Assist Device Implantation,Thessaloniki,,Greece,October 2012
18,19,NCT03239535,Critical Limb Ischemia,Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy,Mesenchymal stem cells|Normal saline,Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy,Moscow,,Russian Federation,"October 1, 2013"
19,20,NCT01453738,Osteoarthritis of Knee,Allogeneic Mesenchymal Stem Cells in Osteoarthritis,Ex- vivo cultured adult allogeneic MSCs|Plasmalyte-A,"A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee",Bangalore|Manipal|Mumbai|Pune|Lucknow,Karnataka|Karnataka|Maharashtra|Maharashtra|Uttar Pradesh,India|India|India|India|India,November 2011
20,21,NCT02467387,Non-Ischemic Heart Failure,A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure,Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Lactated Ringer's Solution,"A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure",Washington|Atlanta|Chicago|Stony Brook|Philadelphia,District of Columbia|Georgia|Illinois|New York|Pennsylvania,United States|United States|United States|United States|United States,"June 1, 2014"
21,22,NCT02866721,Cystic Fibrosis,Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis,Mesenchymal Stem Cells,"A Phase I, Single Center, Open Label, Single Dose, Dose Escalation Study Assessing the Safety and Tolerability of AllogeneiC MEsenchymAl Stem CEll Infusion in Adults With Cystic Fibrosis-CEASE CF",Cleveland,Ohio,United States,August 2016
22,23,NCT02104440,Cytopenia,Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro,"Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro""",,Salamanca,Salamanca/Castilla León,Spain,October 2013
23,24,NCT05086939,Knee Osteoarthritis,Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis.,Autologous MSCs|Allogenic MSCs|Hyaluronic Acid,"Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis",Barcelona|Madrid|Madrid|Madrid|Murcia|Málaga|Pamplona|Salamanca|Valladolid,,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,"May 26, 2021"
24,25,NCT02421484,Septic Shock,Cellular Immunotherapy for Septic Shock: A Phase I Trial,Allogeneic mesenchymal stromal cells,Cellular Immunotherapy for Septic Shock: A Phase I Trial,Ottawa,Ontario,Canada,May 2015
25,26,NCT02677350,Crohn's Disease|Fistulizing Crohn's Disease|Stem Cells,AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE),Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs),"A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.",Miami,Florida,United States,"December 1, 2019"
26,27,NCT04876326,"Multiple System Atrophy|Parkinsonism|Multiple System Atrophy, Parkinson Variant",Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy,Autologous Adipose Mesenchymal Stem Cell Implantation|Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation,Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy,Jakarta Pusat,DKI Jakarta,Indonesia,"October 5, 2020"
27,28,NCT03522545,Treatment-resistant Bipolar Depression,Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression,Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Placebo,Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression,Houston,Texas,United States,"June 1, 2021"
28,29,NCT00749164,Graft-Versus-Host Disease,Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment,MSC transplantation,Allogeneic Mesenchymal Stem Cell Infusion for Treatment Of Steroid Resistant GVHD,Jerusalem,,Israel,September 2009
29,30,NCT02140528,Tibial Fracture,Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures,Mesenchymal stem cell injection|Placebo,Evaluation the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures,Tehran,,"Iran, Islamic Republic of",August 2013
30,31,NCT01448434,Osteoarthritis of Knee Joint,Allogeneic Mesenchymal Stem Cells for Osteoarthritis,Ex- vivo cultured adult allogeneic MSCs|Plasmalyte-A,"A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee",Kuala Lumpur|Kuala Lumpur|Kuala Lumpur|Kuala Lumpur,Federal territory|Selangor|Selangor|Selangor,Malaysia|Malaysia|Malaysia|Malaysia,September 2011
31,32,NCT02150551,Inflammatory Bowel Diseases,Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease,Allogeneic bone marrow-derived mesenchymal stromal cells,Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease,Washington,District of Columbia,United States,September 2015
32,33,NCT03673748,Lupus Nephritis|Lupus Erythematosus,Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells,Mesenchymal stromal cells (MSC)|Placebo,A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Lupus Nephritis,Valladolid,,Spain,December 2022
33,34,NCT01297413,Ischemic Stroke,A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke,Allogeneic adult mesenchymal bone marrow stem cells,"A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke",Gilbert|Orange|San Diego,Arizona|California|California,United States|United States|United States,February 2011
34,35,NCT03967275,Bone Marrow Donor,Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn,bone marrow harvest,Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn SyMbOL Pre Clinical Study,Paris,,France,"September 9, 2020"
35,36,NCT03562065,Lupus Erythematosus|Stem Cell Transplant,Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord,mesenchymal stem cells,Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord,Paris,,France,"September 11, 2019"
36,37,NCT03509870,Diabetic Foot Ulcer,Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds,mesenchymal stromal cells,Uncontrolled Non-randomised Single Dose Study of Topically Applied Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells (REDDSTAR (ORBCEL-M)) in Patients With Non-healing Neuroischaemic Diabetic Foot Wounds',Gentofte,,Denmark,"June 1, 2018"
37,38,NCT02687646,Acute Graft Versus Host Disease,Clinical Trial With MSC for Graft Versus Host Disease Treatment,Adult Allogeneic Mesenchymal cells from adipose tissue.,Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro,Pamplona|Córdoba|Murcia|Málaga|Salamanca|Sevilla,Navarra,Spain|Spain|Spain|Spain|Spain|Spain,May 2016
38,39,NCT01849159,Pulmonary Emphysema,"Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema",Mesenchymal stem cells|Reference therapy: 400 mL of 0.9% NaCl solution,"Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema",Moscow,Moscow Region,Russian Federation,March 2014
39,40,NCT00721045,Heart Failure,A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure,Mesenchymal Precursor Cells (MPCs)|Mesenchymal Precursor Cells (MPCs)|Mesenchymal Precursor Cells (MPCs)|standard-of-care treatment with mock mapping and injection procedures.|standard-of-care treatment with mock mapping and injection procedures.|standard-of-care treatment with mock mapping and injection procedures.,A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure,Gilbert|La Jolla|Minneapolis|Pittsburgh|Houston|Seattle,Arizona|California|Minnesota|Pennsylvania|Texas|Washington,United States|United States|United States|United States|United States|United States,August 2008
40,41,NCT01484574,Critical Limb Ischemia|Buerger's Disease,A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease,Allogeneic Mesenchymal Stem Cells|Allogeneic Mesenchymal Stem Cells,"A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease",New Delhi|Gurgaon|Bangalore|Bangalore|Mangalore|Chennai|Chennai|Chennai|Kolkata|Kolkata,Delhi|Haryana|Karnataka|Karnataka|Karnataka|Tamil Nadu|Tamil Nadu|Tamil Nadu|West Bengal|West Bengal,India|India|India|India|India|India|India|India|India|India,January 2012
41,42,NCT04780685,Covid19,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,hMSC,"A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate to Severe ARDS Due to COVID-19",Fullerton|Santa Monica,California|California,United States|United States,"March 20, 2021"
42,43,NCT02387151,Rejection|Graft Loss,Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients,mesenchymal stromal cells,Safety of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients,Leiden,,Netherlands,March 2015
43,44,NCT05286255,COVID-19 Pneumonia|Viral Pneumonia,Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias,Allogeneic Mesenchymal Stromal Cells,"Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: An Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)",Charleston,South Carolina,United States,"May 4, 2022"
44,45,NCT04869761,"Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies",Stem Cell Therapy for Chronic Kidney Disease,Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions,Allogeneic Mesenchymal Stem Cell Therapy in Patients With Chronic Kidney Disease: A Phase I Study,Jacksonville|Rochester,Florida|Minnesota,United States|United States,"October 7, 2021"
45,46,NCT02509156,Cardiomyopathy Due to Anthracyclines,Stem Cell Injection in Cancer Survivors,Allo-MSCs|Placebo,"A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy",Stanford|Gainesville|Miami|Indianapolis|Louisville|Minneapolis|Houston,California|Florida|Florida|Indiana|Kentucky|Minnesota|Texas,United States|United States|United States|United States|United States|United States|United States,August 2016
46,47,NCT04432545,Systemic Sclerosis Pulmonary|Pulmonary Hypertension|Pulmonary Fibrosis,Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement,Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly,Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment,Chía,Chia,Colombia,
47,48,NCT04535856,Covid19|Corona Virus Infection|SAR,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,allogeneic mesenchymal stem cell|Placebo,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Makassar,,Indonesia,"November 14, 2020"
48,49,NCT04357600,Liver Cirrhoses,Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B,Allogeneic Umbilical Cord Mesenchymal Stem Cell,Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B: Phase I/ II Study,Jakarta,DKI Jakarta,Indonesia,"May 17, 2018"
49,50,NCT01591200,Alcoholic Liver Cirrhosis,Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis,Allogeneic Mesenchymal Stem Cells|Allogeneic Mesenchymal Stem Cells|Allogeneic Mesenchymal Stem Cells,"A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis",Hyderabad|Hyderabad|Bangalore|Mangalore|Mumbai|Mumbai|Pune|Pune|Jaipur|Lucknow,Andhra Pradesh|Andhra Pradesh|Karnataka|Karnataka|Maharashtra|Maharashtra|Maharashtra|Maharashtra|Rajasthan|Uttar Pradesh,India|India|India|India|India|India|India|India|India|India,June 2012
50,51,NCT01946048,Ischemic Cardiomyopathy,Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy,mesenchymal stem cells,Safety and Efficacy Investigation of Patients With Ischemic Cardiomyopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells,Shijiazhuang,Hebei,China,October 2013
51,52,NCT04466007,Limb Ischemia|Diabetic Foot,Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia,High dose allogeneic mesenchymal stromal cells|Low dose allogeneic mesenchymal stromal cells|Placebos,"Multicenter, Randomized, Dose-search, Parallel, Double-blind, and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Intramuscular Administration of Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia Without Possibility of Revascularization",Alicante|Madrid|Madrid|Madrid|Murcia|Pamplona|Salamanca|Sevilla|Valencia|Valladolid,,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,"January 11, 2021"
52,53,NCT01795950,Pulmonary Arterial Hypertension,Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH),PLX-PAD,A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH,Brisbane|Melbourne,Queensland,Australia|Australia,April 2013
53,54,NCT03602872,Knee Osteoarthritis,Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis,Human allogeneic mesenchymal bone marrow derived stem cells,"Phase I, Open Label Study to Assess the Safety and Tolerance of a Single Intraarticular Dose of STEMEDICA's Human Allogeneic Bone Marrow Derived Mesenchymal Stem Cells, in Subjects With Knee Osteoarthritis.",Tijuana,Baja California,Mexico,August 2019
54,55,NCT02619877,Diabetic Foot Ulcer,Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers,ALLO-ASC-DFU|Standard therapy,"Phase 2 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Comparator-controlled, Single-blind, Parallel-group, Multi-center Study",Guro-gu|Nowon-Gu|Seodaemun-Gu|Songpa-Gu,Seoul|Seoul|Seoul|Seoul,"Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of",October 2015
55,56,NCT02619851,Burn Injury,A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects,ALLO-ASC-DFU|Conventional Therapy,"A Phase II Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects: Controlled, Parallel, Multicenter",Seoul,,"Korea, Republic of",December 2015
56,57,NCT03056742,Critical Limb Ischemia Due to Buerger's Disease,A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease,Stempeucel(R),"A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease",New Delhi|Bangalore|Chennai|Chennai|Chennai|Chennai|Kolkata|Kolkata,Delhi|Karnataka|Tamil Nadu|Tamil Nadu|Tamil Nadu|Tamil Nadu|West Bengal|West Bengal,India|India|India|India|India|India|India|India,"February 20, 2017"
57,58,NCT03406585,Type1 Diabetes Mellitus,Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes,ProTrans: Allogeneic transplantation with WJMSCs|Placebos,"A Double-blinded, Randomized, Placebo-controlled Trial With Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells (WJMSCs) for Preserving Endogenous Insulin Production in Adult Patients Diagnosed for Type 1 Diabetes",Stockholm,,Sweden,"November 28, 2017"
58,59,NCT04348461,COVID|Respiratory Distress Syndrome,BAttLe Against COVID-19 Using MesenchYmal Stromal Cells,Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,"Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19",Madrid,,Spain,"May 6, 2020"
59,60,NCT04476901,Non-ischemic Dilated Cardiomyopathy,Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy,allogeneic human mesenchymal stem cells (hMSCs)|Placebo,"A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy",Stanford|Miami|Louisville|Houston,California|Florida|Kentucky|Texas,United States|United States|United States|United States,"May 7, 2021"
60,61,NCT02630836,Femoral Neck Fracture,Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture,XCEL-MT-OSTEO-BETA|Surgical treatment,A Pilot Clinical Trial of ex Vivo Expanded Allogenic Adult Stem Cells Combined With Allogenic Human Bone Tissue (XCEL-MT-OSTEO-BETA) in Proximal Femur Fractures in Elderly Patients,,,,December 2015
61,62,NCT04501354,Osteoporosis,Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients,Mesenchymal Stem Cell,Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients (Clinical Trial),Jakarta Pusat,DKI Jakarta,Indonesia,August 2020
62,63,NCT04590118,Ischemic Stroke,Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST),it-hMSC|Placebo,"A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Multicenter, Blind, Randomized, Placebo Controlled Single Injection of It-hMSC in Patients With Ischemic Stroke",Beijing,,China,"April 26, 2021"
63,64,NCT04361942,COVID-19 Pneumonia,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Mesenchymal Stromal Cells|Placebo,"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)",Valladolid,,Spain,"May 1, 2020"
64,65,NCT01781390,Acute Myocardial Infarction,Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction,Placebo|Mesenchymal Precursor Cells (MPC) 12.5 M|Mesenchymal Precursor Cells (MPC) 25 M,"A Prospective, Double-Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-Elevation Myocardial Infarction",,,,"March 11, 2013"
65,66,NCT02594839,Idiopathic Interstitial Pneumonia|Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis,Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease,Bone marrow mesenchymal stem cells|Placebo,A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease,Moscow,,Russian Federation,February 2013
66,67,NCT05113342,Multiple Myeloma|Relapse Multiple Myeloma,Descartes-25 in Relapsed/Refractory Multiple Myeloma,Descartes-25,Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma,Bethesda|Madison,Maryland|Wisconsin,United States|United States,"November 25, 2021"
67,68,NCT02625246,Bronchiectasis,Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis,hMSCs,"A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis",Miami,Florida,United States,"February 4, 2016"
68,69,NCT04348435,COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",HB-adMSCs|Placebos,"A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Sugar Land,Texas,United States,"May 14, 2020"
69,70,NCT03137199,Asthma,Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma,hMSCs,"A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma",Miami,Florida,United States,"June 22, 2017"
70,71,NCT04545307,Pulp Necroses|Apical Periodontitis,Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis,Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis,Transplantation of Allogeneic Mesenchymal Stromal Cells in Patients With Immature Apex Teeth With Pulp Necrosis and Chronic Apical Periodontitis,San Antonio de los Altos,Miranda,Venezuela,"November 27, 2019"
71,72,NCT03171194,System; Lupus Erythematosus,Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus,Low Dose Mesenchymal Stem Cells (MSCs),A Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus,Atlanta|Charleston,Georgia|South Carolina,United States|United States,"April 27, 2017"
72,73,NCT02893306,Type 1 Diabetes Mellitus,MSC Administration for the Management of Type 1 Diabetic Patients,MSCs,Phase 2 Study of Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus.,Santiago,Region Metropolitana,Chile,March 2012
73,74,NCT02633163,Systemic Lupus Erythematosus,Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE),Low Dose Mesenchymal Stem Cells (MSCs)|High Dose Mesenchymal Stem Cells (MSCs)|Placebo Infusion,A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus,Los Angeles|San Diego|Atlanta|Chicago|Manhasset|Rochester|Chapel Hill|Oklahoma City|Charleston,California|California|Georgia|Illinois|New York|New York|North Carolina|Oklahoma|South Carolina,United States|United States|United States|United States|United States|United States|United States|United States|United States,"October 26, 2018"
74,75,NCT04654286,Brachial Plexus Neuropathies,Human Amniotic Membrane and Mesenchymal Stem Cells Composite,Nerve transfer procedure|Nerve transfer with HAM-AdMSC composite wrapping,Clinical Outcomes of Human Amniotic Membrane and Allogeneic Mesenchymal Stem Cells Composite Augmentation for Nerve Transfer Procedure in Brachial Plexus Injury Patients,Surabaya,East Java,Indonesia,"November 17, 2016"
75,76,NCT01753440,Coronary Artery Disease|Ischemic Cardiomyopathy,Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy,Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).,Study on the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Implantation Combined With Bypass Grafting in Patients With Coronary Artery Disease and Ischemic Cardiomyopathy.,Thessaloniki,,Greece,November 2012
76,77,NCT03973827,Type1diabetes,Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes,ProTrans,"An Open Label, Parallel Single Center Trial of Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells Repeatedly Treated to Preserve Endogenous Insulin Production in Adult Patients Diagnosed With Type 1 Diabetes",Huddinge,,Sweden,"May 17, 2019"
77,78,NCT02323789,Recessive Dystrophic Epidermolysis Bullosa,Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa,Mesenchymal stromal cells,A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa,London,,United Kingdom,June 2015
78,79,NCT03079401,Hypoplastic Left Heart Syndrome|Atrioventricular Canal,Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle,MPC; rexlemestrocel-L,Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle,Boston,Massachusetts,United States,"November 27, 2017"
79,80,NCT05061030,Type1diabetes,Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents,the ATMP Protrans,"A Double-blinded, Randomized, Parallel, Placebo-controlled Trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents",Uppsala,,Sweden,"January 14, 2022"
80,81,NCT03183804,Diabetic Foot Ulcer,A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial,ALLO-ASC-DFU|Standard therapy,A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 2 Clinical Trial of ALLO-ASC-DFU-201,Seoul|Seoul|Seoul|Seoul,,"Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of","April 24, 2016"
81,82,NCT01392625,Non-ischemic Dilated Cardiomyopathy,PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study),Autologous hMSCs|Allogeneic hMSCs,"A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.",Miami,Florida,United States,"May 19, 2011"
82,83,NCT05060107,"Osteoarthritis, Knee",Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1),Exosomes (sEVs),A Phase I Study Aiming to Assess Safety and Efficacy of a Single Intra-articular Injection of MSC-derived Exosomes (CelliStem®OA-sEV) in Patients With Moderate Knee Osteoarthritis (ExoOA-1),,,,"October 5, 2021"
83,84,NCT01843387,Diabetic Nephropathy|Type 2 Diabetes,Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy,Mesenchymal Precursor Cells (MPCs)|Mesenchymal Precursor Cells (MPCs),"A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes",Clayton|Melbourne,,Australia|Australia,July 2013
84,85,NCT03356821,Perinatal Arterial Ischemic Stroke|Neonatal Stroke,Perinatal Arterial Stroke Treated With Stromal Cells Intranasally,Mesenchymal Stem Cells,Adult Mesenchymal Stromal Cells to Regenerate the Neonatal Brain: the PASSIoN Trial (Perinatal Arterial Stroke Treated With Stromal Cells IntraNasally),Utrecht,,Netherlands,"February 11, 2020"
85,86,NCT01087996,Stem Cell Transplantation,The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study),Auto-hMSCs|Allo-hMSCs,"A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction",Miami|Baltimore,Florida|Maryland,United States|United States,March 2010
86,87,NCT01576328,Type 2 Diabetes,Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes,Mesenchymal Precursor Cells (MPCs)|Mesenchymal Precursor Cells (MPCs)|Mesenchymal Precursor Cells (MPCs),"A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin",Garden Grove|Miami|Orlando|Baton Rouge|New Orleans|Butte|Henderson|Las Vegas|Newington|Cincinnati|Dayton|Dallas|Houston|San Antonio|Salt Lake City|Norfolk|Richmond|Olympia,California|Florida|Florida|Louisiana|Louisiana|Montana|Nevada|Nevada|New Hampshire|Ohio|Ohio|Texas|Texas|Texas|Utah|Virginia|Virginia|Washington,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,April 2012
87,88,NCT05344157,"Osteoarthritis, Knee",A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis,XSTEM-OA,"A First-in-Human Open-Label Phase 1/2a Study to Evaluate Safety, Tolerability and Efficacy of a Single Intra-Articular Injection of Allogeneic Mesenchymal Stem Cells Selected for Integrin α10β1 (XSTEM-OA) in Adult Patients With Symptomatic Knee Osteoarthritis",Camberwell,Victoria,Australia,"June 22, 2022"
88,89,NCT02579369,Dystrophic Epidermolysis Bullosa,Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa,Allogeneic mesenchymal stem cells|Polyurethene Film,A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa,Gangnam Gu,Seoul,"Korea, Republic of",October 2015
89,90,NCT05333029,Graft Versus Host Disease,Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD,Allogeneic mesenchymal stromal cells (MSCs)|Extracorporeal photopheresis (ECP),A Phase II Study of Combination Treatment With Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for High-Risk and Steroid-Refractory Acute GVHD,Cleveland,Ohio,United States,October 2022
90,91,NCT04314687,Cerebral Palsy,Stem Cell and Conditioned Medium for Cerebral Palsy,Umbilical Cord Mesenchymal Stem Cells|Conditioned Medium|Standard Therapy,Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children,Jakarta,,Indonesia,"October 13, 2021"
91,92,NCT04506073,Parkinson's Disease,Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD,MSC+placebo|MSC|Placebo,"A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease",Houston,Texas,United States,"November 9, 2020"
92,93,NCT04366323,Sars-CoV2,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",Jerez de la Frontera|Córdoba|Granada|Sevilla|Sevilla|Sevilla,Cádiz,Spain|Spain|Spain|Spain|Spain|Spain,"April 27, 2020"
93,94,NCT01222039,Graft Versus Host Disease|Chronic and Expanded Graft Versus Host Disease|Immune System Diseases,Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.,Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.,"Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.",Jerez de la Frontera|Granada.|Sevilla|Valencia,Cádiz.,Spain|Spain|Spain|Spain,June 2010
94,95,NCT02398604,Hypoplastic Left Heart Syndrome,Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome,Allo-hMSCs|Placebo,Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.,Baltimore|Baltimore,Maryland|Maryland,United States|United States,April 2015
95,96,NCT02685098,Ischemia|Peripheral Arterial Disease|Peripheral Vascular Disease|Vascular Disease|Arterial Occlusive Disease|Arteriosclerosis|Atherosclerosis|Cardiovascular Disease|Pathologic Processes|Orthopedic Procedures|Amputation,A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation,Allogeneic bone marrow derived mesenchymal stem cells,A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation,Indianapolis,Indiana,United States,January 2017
96,97,NCT02192736,Asthma,Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma,Trophic factors from umbilical cord mesenchymal stem cells,Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma,Panama City,,Panama,July 2014
97,98,NCT03211793,Systemic Sclerosis|Digital Ulcer,Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis,Mesenchymal stromal cells|Placebo,Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis: the MANUS Trial,Utrecht,,Netherlands,"October 6, 2021"
98,99,NCT02003131,Osteoarthritis of the Knee,Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis,Trophic factors from umbilical cord mesenchymal stem cells,Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis,Panama City,,Panama,December 2013
99,100,NCT04918706,Pulmonary Emphysema|Mesenchymal Stromal Cells,Allogeneic MSC Treatment for Pulmonary Emphysema,Allogeneic MSC|Placebo,An Explorative Study for Halting Inflammation in Patients With Emphysema by Administration of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells.,Leiden,,Netherlands,"June 25, 2019"
100,101,NCT03487731,Facetogenic Back Pain|Back Pain,Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain,Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Placebo,"A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to EValuate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain",Miami,Florida,United States,"December 1, 2020"
101,102,NCT00549913,Degenerative Disc Disease|Spondylolisthesis|Spinal Stenosis,Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF),NeoFuse|posterolateral spinal fusion with instrumentation,A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.,New York,New York,United States,October 2007
102,103,NCT03589287,Knee Osteoarthritis,Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis,Chondrochymal®,A Phase I/IIa Clinical Study of Treatment for Knee Osteoarthritis by Intra-articular Injection of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells.,Taipei,,Taiwan,"May 2, 2018"
103,104,NCT00810212,Degenerative Disc Disease|Degenerative Spondylolisthesis|Spinal Stenosis,Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion,PLF with autograft|PLF with NeoFuse|PLF with NeoFuse|PLF with NeoFuse,"A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With Mastergraft Granules in Subjects Undergoing Posterolateral Lumbar Fusion With Instrumentation",Plano,Texas,United States,November 2008
104,105,NCT01540292,Crohn's Disease,Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,Mesenchymal Stem Cells (MSC),Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,Liège,,Belgium,"February 1, 2013"
105,106,NCT03905824,Osteochondral Fracture of Talus,The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus,Allogenic stromal mesenchymal cells derived from the umbilical cord|Debridement and microfracture,"Randomized, Multicentric, Prospective, Double-blind Study: Effectiveness of Adding Allogenic Stem Cells to a Platelet-poor Plasma Scaffold After Arthroscopic Debridement and Microfractures in Patients With Osteochondral Lesions of the Talus",Santiago,Independencia,Chile,"January 15, 2019"
106,107,NCT03186417,Rheumatoid Arthritis,Mesenchymal Stem Cells in Early Rheumatoid Arthritis,2 million hMSC/kg|4 million hMSC/kg|6 million hMSC/kg|placebo,Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial,Cleveland|Cleveland,Ohio|Ohio,United States|United States,"December 15, 2017"
107,108,NCT05520086,Chronic Conjunctivitis|Stevens-Johnson Syndrome|Lyell Syndrome|Pemphigoid,Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.,Single Dose|Double Dose,"Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement.",Oviedo|Barakaldo|Alcázar De San Juan|Córdoba|Madrid|Madrid|Madrid|Valladolid,Asturias|Bizkaia|Ciudad Real,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,September 2022
108,109,NCT05177003,Crohn Disease|Ano Fistula,Study of the 12-month Efficacy of Stem Cell Injection in Crohn's Disease With Complex Ano-perineal Fistula,,Study of the 12-month Efficacy of Stem Cell Injection in Crohn's Disease With Complex Ano-perineal Fistula,Paris|Rennes,,France|France,"July 2, 2021"
109,110,NCT00186914,Osteodysplasia,Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation,Marrow stromal cell infusion,Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation: A Phase I Study,Memphis,Tennessee,United States,July 1999
110,111,NCT05165017,Pitt Hopkins Syndrome,Safety & Efficacy of AlloRx SC® in PTHS Patients,AlloRx Stem Cells®|Placebo control,Randomized Double Blind Placebo Controlled Study of the Safety & Efficacy of Therapeutic Treatment With AlloRx Stem Cells® in Patients With Pitt Hopkins Syndrome (Phase 1/2 Study),,,,December 2021
111,112,NCT05157958,Dystrophic Epidermolysis Bullosa,Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa,ALLO-ASC-SHEET|Vehicle Control,"Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients",,,,"March 1, 2022"
112,113,NCT04340609,Acute Myocardial Infarction,Stem Cell in Acute Myocardial Infarction,Mesenchymal Stem Cells,Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Myocardial Infarction,Jakarta,,Indonesia,"March 11, 2019"
113,114,NCT04314661,"Osteoarthritis, Knee",Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis,Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome,Innovative Osteoarthritis Therapy Using Combination of Mesenchymal Stem Cell (MSC) and Conditioned Medium (CM): A Comparative Study on Arthroscopy and Non-Arthroscopy,Jakarta Pusat,DKI Jakarta,Indonesia,"August 3, 2020"
114,115,NCT04326959,Keloid,"Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid",Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Conditioned Medium|Triamcinolone Acetonide,"Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study",,,,"September 1, 2020"
115,116,NCT04315025,Retinitis Pigmentosa,Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa,Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Conditioned Medium (CM),Safety Issues of Peribulbar Injection of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) in Patients With Retinitis Pigmentosa,Jakarta|Yogyakarta,DKI Jakarta|Special Region,Indonesia|Indonesia,"October 7, 2018"
116,117,NCT02145923,Neutropenic Enterocolitis|Myeloablative Chemotherapy Induced Bone Marrow Aplasia,Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis,Peripheral blood stem cell mobilisation and collection|High-dose chemotherapy|Bone marrow derived allogeneic MMSCs infusion|Autologous peripheral blood stem cells infusion,Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.,Moscow,,Russian Federation,May 2014
117,118,NCT01290367,Degenerative Disc Disease,Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain,Single Dose MPCs Injection|Single injection of saline solution|Single injection of hyaluronic acid|Single Dose MPCs Injection,"A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain",Scottsdale|Sacramento|Santa Monica|Walnut Creek|Denver|Loveland|Atlanta|Charlotte|Austin|Richmond|Richmond|Edmonds|Charleston|Clayton,Arizona|California|California|California|Colorado|Colorado|Georgia|North Carolina|Texas|Texas|Virginia|Washington|West Virginia|Victoria,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia,August 2011
118,119,NCT01775774,Acute Respiratory Distress Syndrome,Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome,Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells,A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome,San Francisco|Stanford|Boston|Pittsburgh,California|California|Massachusetts|Pennsylvania,United States|United States|United States|United States,July 2013
119,120,NCT01956903,Chronic Graft-Versus-Host Disease,Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.,Allogenic Mesenchymal Stem Cell,Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell,Madrid,,Spain,January 2010
120,121,NCT04073472,"Crohn's Disease|Fistula|Anal Fistula|Pouch, Ileal|Pouches, Ileoanal",Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's,mesenchymal stem cells (MSCs),A Phase I Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch,,,,"June 1, 2021"
121,122,NCT02824653,Graft Versus Host Disease,Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD,Mesenchymal Stem Cells,Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD- A Phase I/II Clinical Trial,Rawalpindi,Punjab,Pakistan,January 2015
122,123,NCT01983709,Prostate Cancer,Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer,Allogeneic Human Mesenchymal Stem Cells,A Phase 1 Study of Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer,Baltimore,Maryland,United States,October 2013
123,124,NCT05522569,"Acute Ischemic Stroke|Mesenchymal Stem Cells|Stroke, Acute|Stroke/Brain Attack|Stroke, Ischemic",Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND),Allogeneic human mesenchymal stem cells (Allo-hMSCs),Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (Allo-hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND),Miami,Florida,United States,
124,125,NCT02675556,Treatment Resistant Depression,Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression,Allo-hMSCs|Placebo,"A Phase I, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Treatment Resistant Depression.",Miami,Florida,United States,"October 31, 2017"
125,126,NCT02672267,Myocardial Infarction,A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction,Stem cells|Placebo,"A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction",Astana,,Kazakhstan,July 2014
126,127,NCT03929120,Interstitial Lung Disease|Connective Tissue Diseases,Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD),Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs),A Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients With Connective Tissue Disorders,Jacksonville,Florida,United States,"November 5, 2019"
127,128,NCT02731586,Edentulous Alveolar Ridge,Effect on Allogenic Mesenchymal Stem Cells on Osseointegration of Dental Implants,Allogenic Mesenchymal stem cells,"Comparative Clinical Evaluation of Osseointegration of Dental Implants Placed With and Without, the Use of Dental Pulp-derived Allogenic Mesenchymal Stem Cells.",Vikarabad,Telangana State,India,January 2016
128,129,NCT02097641,"Respiratory Distress Syndrome, Adult",Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START),Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Plasma-Lyte A,"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)",San Francisco|Stanford|Boston|Saint Paul|Columbus|Pittsburgh,California|California|Massachusetts|Minnesota|Ohio|Pennsylvania,United States|United States|United States|United States|United States|United States,"March 15, 2014"
129,130,NCT04519671,Perianal Crohn Disease|Perianal Fistula|Crohn Disease,Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease,Mesenchymal Stem Cells|Placebo,A Phase IB/IIA Study of Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease,Cleveland,Ohio,United States,"November 19, 2020"
130,131,NCT02763423,"Ketoacidosis, Diabetic",Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis,umbilical cord mesenchymal stem cell,The Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation to Treat New-onset Type 1 Diabetes With Diabetic Ketoacidosis,Nanjing,Jiangsu,China,January 2009
131,132,NCT01763086,"Stem Cell Transplantation, Hematopoietic|Mesenchymal Stem Cells|Poor Graft Function|Hematological Diseases",Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant,Mesenchymal stem cells,Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation,Guangzhou,Guangdong,China,January 2013
132,133,NCT04791878,Perianal Fistula Due to Crohn's Disease (Disorder),Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease,Mesenchymal stem cells,A Phase I Study of Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease,Cleveland,Ohio,United States,"April 1, 2021"
133,134,NCT01856140,Lateral Epicondylitis,Treatment of Tendon Injury Using Mesenchymal Stem Cells,ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection,Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study,Seoul,,"Korea, Republic of",May 2013
134,135,NCT02611167,Parkinson's Disease,Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease,Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg),Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease,Houston,Texas,United States,"November 1, 2017"
135,136,NCT04388761,Ischemia Reperfusion Injury,Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI),Allogeneic adipose derived mesenchymal stem cells,Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI),Jacksonville,Florida,United States,"September 28, 2020"
136,137,NCT01586312,"Osteoarthritis, Knee|Arthritis of Knee|Knee Osteoarthritis",Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells,Allogenic mesenchymal stromal cells injection|Hyaluronic Acid,Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Mesenchymal Stromal Cells From Valladolid,Barcelona|Valladolid,,Spain|Spain,April 2012
137,138,NCT04519697,Rectovaginal Fistula|Crohn Disease|Crohn Disease of Vulva|Rectolabial; Fistula,Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease,Mesenchymal Stem Cells|Placebo,A Phase IB/IIA Study of Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in the Setting of Crohn's Disease.,Cleveland,Ohio,United States,"October 28, 2020"
138,139,NCT01914887,Ulcerative Colitis,Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis,Allogeneic adipose tissue-derived mesenchymal stem cells,A Phase I/IIa Clinical Trial to Evaluate Safety and Efficacy of Adipose Tissue-derived Mesenchymal Stem Cells (ASC) on Induction to Remission in Ulcerative Colitis,Madrid,,Spain,June 2013
139,140,NCT05039411,Perianal Fistula Due to Crohn's Disease|Fistula in Ano,Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease,Human umbilical cord mesenchymal stem cells (UC-MSCs),A Phase I Study of the Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for Perianal Fistulas in Patients With Crohn's Disease,Kuala Lumpur,,Malaysia,"March 1, 2022"
140,141,NCT04382547,"COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2",Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Standard treatment according to the Clinical protocols,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Minsk,,Belarus,"May 11, 2020"
141,142,NCT04519684,Ileal Pouch|Crohn Disease,Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease,Mesenchymal stem cells|Placebo,A Phase IB/IIA Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch,Cleveland,Ohio,United States,"October 28, 2020"
142,143,NCT02857010,Acute on Chronic Hepatic Failure,Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure,Allogenic mesenchymal stem cells|Placebo,Therapeutic Effects of Allogenic Mesenchymal Stem Cells in Cirrhotic Patients With Acute-on-chronic Liver Failure. A Double-blind Randomized Placebo-controlled Trial,Barcelona,,Spain,February 2016
143,144,NCT01860417,Degenerative Disc Disease|Intervertebral Disc Disease|Low Back Pain,Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV),Allogenic Mesenchymal Stromal Cells|Mepivacaine,Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure,Valladolid|Valladolid,,Spain|Spain,April 2013
144,145,NCT03265808,Major Depressive Disorder|Alcohol Use Disorder,Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.,allogeneic human mesenchymal stem cells (allo-hMSCs)|Placebo,"A Phase I/II, Prospective, Randomized, Double-Blind, PlAcebo-ControLled Trial to EvAluate the Potential Efficacy of Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.",Harlingen,Texas,United States,"March 18, 2018"
145,146,NCT04520022,Recessive Dystrophic Epidermolysis Bullosa,Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB,Human Umbilical Cord Blood-derived Mesenchymal Stem Cells,"Single Center, Single Group Assignment, Open Label Trial to Assess Safety and Effectiveness of Intravenous Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With Recessive Dystrophic Epidermolysis Bullosa",Seoul,,"Korea, Republic of","October 13, 2016"
146,147,NCT02412735,Degenerative Disc Disease,Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain,Rexlemestrocel-L|Rexlemestrocel-L + HA Mixture|Placebo,"A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain",Birmingham|Huntsville|Scottsdale|Tempe|El Cajon|Long Beach|Newport Beach|Pasadena|Sacramento|Santa Monica|Santa Monica|Santa Rosa|Walnut Creek|Greenwood Village|Washington|Fernandina Beach|Fort Lauderdale|Oakland Park|Atlanta|Marietta|Boise|Bloomington|Edgewood|Shreveport|Rochester|Shakopee|Las Vegas|Somerset|New York|Rochester|Charlotte|Morrisville|Winston-Salem|Cleveland|Dayton|Edmond|York|Providence|Charleston|Charleston|Plano|Southlake|Tyler|Bountiful|Draper|Saint George|Richmond|Clayton,Alabama|Alabama|Arizona|Arizona|California|California|California|California|California|California|California|California|California|Colorado|District of Columbia|Florida|Florida|Florida|Georgia|Georgia|Idaho|Illinois|Kentucky|Louisiana|Minnesota|Minnesota|Nevada|New Jersey|New York|New York|North Carolina|North Carolina|North Carolina|Ohio|Ohio|Oklahoma|Pennsylvania|Rhode Island|South Carolina|South Carolina|Texas|Texas|Texas|Utah|Utah|Utah|Virginia|Victoria,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia,"March 6, 2015"
147,148,NCT03795974,"Cerebral Palsy, Spastic",Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy,MNC|MSC|Control,"Evaluation of the Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Patients With Spastic Cerebral Palsy on Developmental Function , A Clinical Trial phase2",Tehran|Tehran|Tehran|Tehran,,"Iran, Islamic Republic of|Iran, Islamic Republic of|Iran, Islamic Republic of|Iran, Islamic Republic of","July 23, 2017"
148,149,NCT04615455,"Keratoconjunctivitis Sicca, in Sjogren's Syndrome",Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome,ASCs|Cryostor CS10,A Randomized Clinical Trial Evaluating Allogeneic Adipose-derived MesenchymAl Stem Cells as a Treatment of Dry Eye Disease in Patients With Sjögren's Syndrome,Copenhagen,DK,Denmark,"November 3, 2020"
149,150,NCT03878628,Dry Eye|Kerato Conjunctivitis Sicca|Aqueous Tear Deficiency,Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease,Adipose tissue-derived mesenchymal stem cells,Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease,Copenhagen,DK,Denmark,"October 16, 2019"
150,151,NCT01322906,Liver Failure,Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV),Group 1|Group 2|Group 3,Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by HBV,,,,March 2011
151,152,NCT05017298,Corona Virus Infection|Covid19,Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells,Allogeneic adipose-derived stem cells,Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs),,,,"November 1, 2022"
152,153,NCT04318600,Lupus Nephritis|Mesenchymal Stem Cells,Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis,human amniotic mesenchymal stem cell,Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis,,,,"January 1, 2014"
153,154,NCT02065245,Frailty,AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery,Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Placebo|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs),"A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty",Miami,Florida,United States,"March 3, 2014"
154,155,NCT02298023,Rotator Cuff Tear,Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear),allogenic adipose stem cell injection|fibrin glue/normal saline injection|normal saline injection,Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.,Seoul,,"Korea, Republic of",September 2014
155,156,NCT02215811,"Acute Respiratory Distress Syndrome, Adult",Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells,Mesenchymal stromal cells,Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells,Stockholm|Uppsala,,Sweden|Sweden,March 2014
156,157,NCT05152290,Spinal Cord Injuries,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury,St. John's,,Antigua and Barbuda,January 2022
157,158,NCT02641860,Osteoarthritis,Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis,Mesenchymal progenitor cells,"A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis",Shanghai,Shanghai,China,December 2015
158,159,NCT02013700,Idiopathic Pulmonary Fibrosis (IPF),Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER),Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|matched placebo,"A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis",Miami,Florida,United States,"November 13, 2013"
159,160,NCT05147675,Osteoarthritis|Spinal Arthritis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis,St. John's,,Antigua and Barbuda,December 2021
160,161,NCT05158127,Skin Ulcer,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Skin Ulcer,St. John's,,Antigua and Barbuda,January 2022
161,162,NCT05147701,Eye Diseases|Retinitis Pigmentosa|Glaucoma|Diabetic Retinopathy|Macular Degeneration|Traumatic Optic Neuropathy|Optic Atrophy,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Eye Diseases,St. John's,,Antigua and Barbuda,January 2022
162,163,NCT05018858,Lupus,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus,St. John's,,Antigua and Barbuda,February 2022
163,164,NCT05158933,Ovarian Failure,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Ovarian Failure,St. John's,,Antigua and Barbuda,January 2022
164,165,NCT05158101,Stroke,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Stroke,St. John's,,Antigua and Barbuda,February 2022
165,166,NCT05003960,Autism,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism,St. John's,,Antigua and Barbuda,February 2022
166,167,NCT05147766,Congestive Heart Failure|Angina,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Heart Disease,St. John's,,Antigua and Barbuda,February 2022
167,168,NCT05158439,Tourette Syndrome,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Tourette Syndrome,St. John's,,Antigua and Barbuda,January 2022
168,169,NCT05003908,Diabetes,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Diabetes,St. John's,,Antigua and Barbuda,February 2022
169,170,NCT05147688,Pulmonary Disease|Asthma|Chronic Obstructive Pulmonary Disease,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Pulmonary Diseases,St. John's,,Antigua and Barbuda,December 2021
170,171,NCT05018819,Cerebral Palsy,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy,St. John's,,Antigua and Barbuda,February 2022
171,172,NCT05152394,Parkinson Disease,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Parkinson's Disease,St. John's,,Antigua and Barbuda,January 2022
172,173,NCT05003388,Multiple Sclerosis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis,St. John's,,Antigua and Barbuda,February 2022
173,174,NCT05003934,Rheumatoid Arthritis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Rheumatoid Arthritis,St. John's,,Antigua and Barbuda,February 2022
174,175,NCT05152381,Osteoporosis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Osteoporosis,St. John's,,Antigua and Barbuda,January 2022
175,176,NCT05018832,Traumatic Brain Injury,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury,St. John's,,Antigua and Barbuda,December 2022
176,177,NCT05018767,Frailty,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty,St. John's,,Antigua and Barbuda,February 2022
177,178,NCT05018845,Chronic Kidney Diseases,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Chronic Kidney Disease.,St. John's,,Antigua and Barbuda,February 2022
178,179,NCT05016804,Systemic Sclerosis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis,St. John's,,Antigua and Barbuda,February 2022
179,180,NCT05003947,Inflammatory Bowel Diseases,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease,St. John's,,Antigua and Barbuda,February 2022
180,181,NCT05016817,Idiopathic Pulmonary Fibrosis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis,St. John's,,Antigua and Barbuda,February 2022
181,182,NCT04447833,"ARDS, Human|COVID",Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy,Uppsala,,Sweden,"June 17, 2020"
182,183,NCT05003921,Amyotrophic Lateral Sclerosis,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis,St. John's,,Antigua and Barbuda,February 2022
183,184,NCT04208646,Knee Osteoarthritis,Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis,Mesenchymal progenitor cells|No mesenchymal progenitor cells,"A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis",Beijing|Hangzhou|Shanghai|Shanghai|Shanghai|Shanghai|Shanghai,,China|China|China|China|China|China|China,"May 16, 2020"
184,185,NCT05158114,Testicular Injury|Oligospermia,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Testicular Injury and Oligospermia,St. John's,,Antigua and Barbuda,January 2022
185,186,NCT02013674,Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction,The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study),Allogeneic hMSCs,"A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.",Miami,Florida,United States,"February 13, 2014"
186,187,NCT04184258,Systemic Lupus Erythematosus,Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells,Pooled mesenchymal stem cell|Standard treatment according to the Clinical protocols,Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells,Minsk,,Belarus,"July 1, 2019"
187,188,NCT05042206,Chronic Kidney Disease Stage 3B|Chronic Kidney Disease stage4,Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease,Cellgram-CKD,"An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease",Seoul,,"Korea, Republic of",October 2021
188,189,NCT02587715,"Multiple Sclerosis, Relapsing-Remitting",A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Liberation therapy,"An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",San Fernando,Trinidad,Trinidad and Tobago,February 2015
189,190,NCT02418325,"Multiple Sclerosis, Relapsing-Remitting",A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Liberation therapy,"An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",San Fernando,Trinidad,Trinidad and Tobago,February 2015
190,191,NCT02235844,Duchenne's Muscular Dystrophy,Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD),Umbilical Cord Mesenchymal Stem Cells,Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD),Wichita,Kansas,United States,September 2014
191,192,NCT01678534,Ischemic Stroke,"Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial",Allogenic mesenchymal stem cells from adipose tissue|Placebo,"Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue. Safety Assessment. A Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial.(AMASCIS-01/2011)",Madrid,,Spain,September 2014
192,193,NCT02855112,"Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]",Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients,Adipose derived mesenchymal stem cell,The Effectiveness of Allogeneic Adipose Derived Mesenchymal Stem Cells (ADMSCs) in the Phenotypic Changes of Werdnig Hoffman Patients,Tehran,,"Iran, Islamic Republic of",June 2015
193,194,NCT05016011,"Osteoarthritis, Knee",Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury,Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Marrow cellution,Phase IIb Study Assessing the Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells for Knee Cartilage Injury,Bandar Tun Razak,Wilayah Persekutuan Kuala Lumpur,Malaysia,"July 1, 2020"
194,195,NCT02833792,Alzheimer Dementia,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Placebo,A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease,Santa Monica,California,United States,June 2016
195,196,NCT02384499,Fecal Incontinence,"Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",ALLO-ASC injection|Placebo,"Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",Seoul,,"Korea, Republic of",December 2014
196,197,NCT01649687,Cerebellar Ataxia,Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells,Allogeneic adult adipose-derived mesenchymal stem cells,Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells,Taipei,,Taiwan,May 2012
197,198,NCT04336254,COVID-19,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous saline injection (Placebo),"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial",Wuhan,Hubei,China,"May 6, 2020"
198,199,NCT00447460,Graft-vs-Host Disease (GVHD),Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell,Mesenchymal stem cell (MSC),A Phase I/II Trial in Treating Patients With Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell,Navarra|Barcelona|Barcelona|Salamanca,Pamplona,Spain|Spain|Spain|Spain,January 2007
199,200,NCT04543994,Ulcerative Colitis,Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC),Remestemcel-L|Remestemcel-L|Placebo,"A Phase IB/IIA Study of Remestemcel-L, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative Colitis",Cleveland,Ohio,United States,"November 10, 2020"
200,201,NCT01902082,ARDS,Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome,Mesenchymal stem cells|Placebo,Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome,Shaoxing,Zhejiang,China,November 2012
201,202,NCT02338375,Osteochondral Lesion of Talus,Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product,Cartistem,Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients,Gangnam-Gu,Seoul,"Korea, Republic of",December 2012
202,203,NCT04548583,Crohn Colitis,Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis,Remestemcel-L|Remestemcel-L|Placebo,"A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis",Cleveland,Ohio,United States,"November 4, 2020"
203,204,NCT05532943,Multiple Sclerosis,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,Allogeneic umbilical cord mesenchymal stem cells|Control group,A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,Taichung,Non-US,Taiwan,"December 31, 2022"
204,205,NCT05501418,COVID-19 Infection,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19,Allogeneic umbilical cord mesenchymal stem cells|Controlled normal saline,A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition,Taichung,Non-US,Taiwan,"August 5, 2020"
205,206,NCT01144962,Crohn's Disease|Fistula,Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease,"Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease,Leiden,Zuid Holland,Netherlands,June 2010
206,207,NCT02307435,Non Union Fracture|Metaphyseal Fibrous Defect,Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture,MSC,"Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved",Jakarta Pusat|Propinsi DKI Jakarta,Jakarta|Jakarta,Indonesia|Indonesia,August 2014
207,208,NCT03818854,"Respiratory Distress Syndrome, Adult",Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome,Human Mesenchymal Stromal Cells|Cell Reconstitution Media,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome",Sacramento|San Francisco|San Francisco|Portland|Nashville|Houston|Seattle,California|California|California|Oregon|Tennessee|Texas|Washington,United States|United States|United States|United States|United States|United States|United States,"November 26, 2019"
208,209,NCT04280003,Ischemic Stroke|Adipose Tissue-derived Stem Cell|Functional Status,Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke,Alogenic adipose tissue-derived stem cells|Placebo solution,Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke. A Phase IIB Multicenter Double Blind Placebo Controlled Clinical Trial,Madrid,,Spain,"January 20, 2021"
209,210,NCT03265613,Mesenchymal Stromal Cells|Psoriasis|Drug Toxicity|Drug Effect,Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis,adipose-derived multipotent mesenchymal stem cells,Safety and Efficacy of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Moderate to Severe Psoriasis,Guangzhou,Guangdong,China,"September 24, 2017"
210,211,NCT04087889,Pancreatic Cancer,Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer,HB-adMSCs,Individual Patient Expanded Access IND of Hope Biosciences Allogeneic First Blood Relative Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer,Sugar Land,Texas,United States,
211,212,NCT03800810,"Osteoarthritis, Knee",Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord Blood for Osteoarthritis Management,Hyaluronic Acid|Umbilical Cord Mesenchymal Stem Cell|Recombinant Human Somatropin,Potency of Allogenic Umbilical Cord Mesenchymal Stem Cells for Osteoarthritis Management,Jakarta Pusat,Jakarta,Indonesia,May 2015
212,213,NCT00698191,Refractory Systemic Lupus Erythematosus,Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE),Allogeneic MSC (AlloMSC),Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus,Nanjing,Jiangsu,China,March 2007
213,214,NCT03449082,Lateral Epicondylitis,Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC),High concentration of Allo-ASC|Low concentration of Allo-ASC|Fibrin glue|Normal saline,Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial,Seoul,,"Korea, Republic of","May 4, 2018"
214,215,NCT01526850,Chronic Graft Versus Host Disease,Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease,Biological: mesenchymal stem cell|Cyclosporine and Glucocorticoid,"Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease",Hangzhou,Zhejiang,China,February 2012
215,216,NCT03384433,Cerebrovascular Disorders,Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke,exosome,"Safety and Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosome on Disability of Patients With Acute Ischemic Stroke: a Randomized, Single-blind, Placebo-controlled, Phase 1, 2 Trial",Tehran,,"Iran, Islamic Republic of","April 17, 2019"
216,217,NCT01440309,Primary Biliary Cirrhosis,Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis,Biological: mesenchymal stem cell|ursodeoxycholic acid,"Phase I Clinical Trial, Randomized, Controlled, to Evaluate the Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells From Bone Marrow for Patients With Refractory Primary Biliary Cirrhosis",Beijing,,China,November 2011
217,218,NCT02192749,Autism,Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism,Umbilical cord mesenchymal stem cells,"Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)",Panama City,,Panama,July 2014
218,219,NCT03184935,Myelodysplastic Syndromes,Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS),Allogeneic umbilical cord mesenchymal stem cells|Decitabine,Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS),Hohhot,Inner Mongolia,China,June 2022
219,220,NCT05078385,Burns,Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds,AGLE-102,A Pilot Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Burn Wounds.,,,,July 2022
220,221,NCT00504803,Hematological Malignancies,Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease,Mesenchymal stem cell infusion,Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study,Liege,,Belgium,December 2006
221,222,NCT03180463,Osteonecrosis of Femoral Head,The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH),Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|core decompression,The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC),Hohhot,Inner Mongolia,China,June 2022
222,223,NCT03186456,Cerebral Infarction,The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction,Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Aspirin Tablet,Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction,Hohhot,Inner Mongolia,China,June 2022
223,224,NCT02804945,Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome,Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies,Mesenchymal Stem Cells (MSCs),A Pilot Study of Mesenchymal Stem Cells for Treatment of Acute Respiratory Distress Syndrome in Patients With Malignancies,Houston,Texas,United States,"February 24, 2017"
224,225,NCT01552707,"Lumbar Spondylolisthesis Involving L4-L5, and/or|Degenerative Discopathy Involving L4-L5",Safety Study of Mesenchymal Stem Cells and Spinal Fusion,XCEL-MT-OSTEO-ALPHA|Standard treatment,"""Ex Vivo"" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease",Badalona|Barcelona|Barcelona|Barcelona|Barcelona,Barcelona,Spain|Spain|Spain|Spain|Spain,"July 19, 2012"
225,226,NCT04889963,Adypose Mesenchimal Stem Cell|Ligament Rupture|Ligament Derived Conditined Medium,Regeneration of Posterior Cruciate Ligament Injury Using Hypoxic Conditioned Allogenic Adipose Mesenchymal Stem Cell and Condition Medium,adypose mesenchymal conditioned medium and ligament derived conditioned medium,Regeneration of Posterior Cruciate Ligament Injury Using Hypoxia Conditioned Allogenic Adipose Mesenchymal Stem Cell (AdMSC) and Ligament Derived Condition Medium (Secretome),Sleman,Yogyakarta,Indonesia,"January 1, 2021"
226,227,NCT04909892,Covid19,"Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",COVI-MSC,"A Phase 2a Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",,,,August 2021
227,228,NCT01092026,Allogeneic Stem Cell Transplantation,Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells,cord blood transplantation,A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies,Brussel,,Belgium,November 2010
228,229,NCT02940418,Diabetes Mellitus Type 1,Use of Stem Cells in Diabetes Mellitus Type 1,Adipose mesenchymal cells with bone marrow mononuclear cells,The Use of Mesenchymal Stromal Cells (MSC) in Type 1 Diabetes Mellitus in Adult Humans: Phase I Clinical Trial,Amman,,Jordan,"February 19, 2017"
229,230,NCT03865394,Diabetic Foot Ulcer,Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells,Application of allogeneic ADSC stem cells in fibrin gel|Standard care in diabetic foot ulcer,Evaluation of the Safety and Efficacy of the Treatment of Chronic Wounds in Diabetic Foot Syndrome With the Use of Allogeneic Stem Cells Isolated From Adipose Tissue,Warsaw,,Poland,"July 1, 2019"
230,231,NCT03180450,Heart Failure,The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF),Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|conventional treatment,The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC),Hohhot,Inner Mongolia,China,June 2022
231,232,NCT05152368,Peripheral Neuropathy|Trigeminal Neuralgia,Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy,AlloRx,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Trigeminal Neuralgia and Peripheral Neuropathy,St. John's,,Antigua and Barbuda,January 2022
232,233,NCT03176498,Cerebral Infarction,Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.,Allogeneic umbilical cord mesenchymal stem cell|Aspirin Enteric-coated Tablets & Atorvastatin Calcium,The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.,Hohhot,Inner Mongolia,China,June 2022
233,234,NCT05147779,Erectile Dysfunction|Peyronie's Disease|Interstitial Cystitis,"Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis",AlloRx,"Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis",St. John's,,Antigua and Barbuda,December 2021
234,235,NCT04328714,Acute Leukemia|Myelodysplastic Syndromes,Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease,Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells,Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia,Atlanta|Atlanta|Atlanta,Georgia|Georgia|Georgia,United States|United States|United States,"December 2, 2021"
235,236,NCT04056819,Acute Myocardial Infarction,Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction,Allogeneic umbilical cord mesenchymal stem cells,"A Phase I, Open Label Study to Evaluate the Safety and to Explore Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With ST-elevation Acute Myocardial Infarction",Taichung,Non-US,Taiwan,"May 27, 2019"
236,237,NCT05130983,Crohn Disease|IBD - Irritable Bowel Disease,"A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",Bone Marrow MSC Derived Extracellular Vesicle Isolate,"A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,,,"September 1, 2022"
237,238,NCT03473301,Cerebral Palsy,A Study of UCB and MSCs in Children With CP: ACCeNT-CP,Infusion of allogeneic umbilical cord blood|Infusion of MSCs,A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy,Durham,North Carolina,United States,"April 10, 2018"
238,239,NCT05362786,Chronic Kidney Diseases,Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease,Allogeneic adipose-derived mesenchymal stem cells (MSC)|Allogeneic adipose-derived mesenchymal stem cells (MSC),Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease,Jacksonville|Rochester,Florida|Minnesota,United States|United States,"July 1, 2022"
239,240,NCT04992247,Covid19,"Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",COVI-MSC|Placebo,"A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",,,,November 2022
240,241,NCT04905836,Covid19,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress,COVI-MSC|Placebo,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Brandon|Sarasota|Boise|Boise|Tulsa|Mesquite,Florida|Florida|Idaho|Idaho|Oklahoma|Texas,United States|United States|United States|United States|United States|United States,"November 16, 2021"
241,242,NCT02881476,Amyotrophic Lateral Sclerosis,Therapeutic Treatment of Amyotrophic Lateral Sclerosis,Biological: Cell-based therapy,Application of Wharton's Jelly-derived Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis,,,,November 2015
242,243,NCT04909879,Acute Respiratory Distress Syndrome|Ards,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome,COVI-MSC|Placebo,Treatment of Non-COVID-19 Acute Respiratory Distress Syndrome: A Phase 2 Study of the Efficacy and Safety of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells,,,,September 2021
243,244,NCT02108132,Hemophilia,Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia,Cellular therapy|cellular therapy,Allogenic Mesenchymal Stem Cells in Hemophilia: a Pilot Study,Cairo,,Egypt,August 2014
244,245,NCT04728698,Covid19|ARDS,Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress,COVI-MSC|Placebo,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Fresno,California,United States,March 2021
245,246,NCT05491681,"ARDS, Human",AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial,intravenous delivery of allogeneic bone marrow-derived MSCs,Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL),,,,"September 15, 2022"
246,247,NCT02230514,Atrophic Nonunion of Fracture,Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones,XCEL-MT-OSTEO-ALPHA|autologous iliac crest|Surgery,"A Phase IIa, Single Center, Prospective, Randomized, Parallel, Two-arms, Single-dose, Open-label With Blinded Assessor Pilot Clinical Trial to Assess ex Vivo Expanded Adult Autologous Mesenchymal Stromal Cells Fixed in Allogeneic Bone Tissue (XCEL-MT-OSTEO-ALPHA) in Non Hypertrophic Pseudoarthrosis of Long Bones",Sant Cugat,Barcelona,Spain,"November 20, 2014"
247,248,NCT03994666,Critical Limb Ischemia,Cell Therapy in Critical Limb Ischemia,allogeneic umbilical cord-derived mesenchymal stem cells|Placebo (NaCl),Cell Therapy in Critical Limb Ischemia by Implantation of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells,Reims,,France,September 2019
248,249,NCT04289194,Acute Respiratory Distress Syndrome,Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome,HCR040 (Phase 1)|Placebo (Phase 2)|HCR040 (Phase 2),"Phase 1/2 Clinical Study to Assess the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of HCR040, Allogeneic Adipose-derived Adult Mesenchymal Stem Cells, in Acute Respiratory Distress Syndrome",Barakaldo|Madrid,Bizkaia,Spain|Spain,"December 10, 2019"
249,250,NCT04785027,Traditional Chinese Medicine|Drug Effect|Drug Safety|Psoriasis|Mesenchymal Stromal Cells,Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis,PSORI-CM01 formula|Gu Ben Hua Yu formula|adipose-derived multipotent mesenchymal stem cells,Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Moderate to Severe Psoriasis: a Pilot Study for a Randomized Controlled Trial,Guangzhou,Guangdong,China,"March 17, 2021"
250,251,NCT03113747,Second- or Third-degree Burns,Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs),ALLO-ASCs,Safety and Efficacy Evaluation of Tissue Engineered Construct Based on Allogeneic Adipose-derived Multipotent Mesenchymal Stromal Cells and Platelet-poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds,Kyiv,,Ukraine,"March 25, 2015"
251,252,NCT04255147,Bronchopulmonary Dysplasia,Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia,Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells,Helping Underdeveloped Lungs With Cells (HULC): Mesenchymal Stromal Cells in Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia - Phase 1 Study,Ottawa,Ontario,Canada,June 2022
252,253,NCT04236479,Congenital Heart Disease (CHD),Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP),BM-MSC,Mesenchymal Stromal Cells Delivery Through Cardiopulmonary Bypass in Pediatric Cardiac Surgery,Washington,District of Columbia,United States,"July 29, 2020"
253,254,NCT02587572,Metabolic Disease|Endothelial Dysfunction,Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial,Peripheral Intravenous (IV) infusion of LMSCs,"A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.",,,,December 2022
254,255,NCT00972660,Graft Versus Host Disease,Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease,Mesenchymal stem cell (MSC)|Prednisone and cyclosporine or primary therapies,"A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease",Guangzhou,Guangdong,China,September 2009
255,256,NCT04714801,Lung Transplant Rejection,Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation,adipose derived mesenchymal stromal cells|Saline,"A Danish, Single Centre, Double-blind, Randomized Study Evaluating Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy to Reduce Primary Graft Dysfunction After Lung Transplantation",Copenhagen,,Denmark,"October 1, 2020"
256,257,NCT04341610,Respiratory Tract Diseases,ASC Therapy for Patients With Severe Respiratory COVID-19,Stem Cell Product,"Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study",Copenhagen,,Denmark,"April 20, 2020"
257,258,NCT04433104,COPD,Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease,Umbilical Cord Mesenchymal Stem Cells transplantation|drug therapy according to Vietnamese MOHS procedure,"Allogeneic Human Umbilical Cord-derived Mesenchymal Stem/Stromal Cells for Chronic Obstructive Pulmonary Disease (COPD): Study Protocol for a Matched Case-control, Phase I/II Trial",Hà Nội,Hanoi,Vietnam,"June 9, 2020"
258,259,NCT04467047,COVID-19|Sars-CoV2,Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19,Mesenchymal Stromal Cells infusion,Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19,,,,"July 25, 2020"
259,260,NCT04392206,End Stage Renal Disease,AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses,Adipose Derived Mesenchymal Stem Cells,"A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",Jacksonville,Florida,United States,"May 15, 2020"
260,261,NCT05132972,Covid 19,Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients,Normoxic Allogenic UCMSC|Normal saline solution,Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19,Surakarta|Bandung|Yogyakarta,Central Java|West Java,Indonesia|Indonesia|Indonesia,"January 17, 2021"
261,262,NCT02336646,Critical Limb Ischemia,Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease,Allogenic MSC|Normal saline,Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease,Taipei,,Taiwan,"May 1, 2015"
262,263,NCT02083718,"Stem Cell Transplantation, Hematopoietic|Poor Graft Function|Hematological Diseases",Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function,PBSC|MSCs,G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant,Guangzhou,Guangdong,China,January 2014
263,264,NCT03369275,Septic Shock|Sepsis|Pathologic Processes|Shock|Infection|Systemic Inflammatory Response Syndrome|Inflammation,Cellular Immunotherapy for Septic Shock,Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Placebo,Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial,,,,March 2018
264,265,NCT04602104,Acute Respiratory Distress Syndrome,A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS,low dose hMSC-Exos|medium dose hMSC-Exos|high dose hMSC-Exos|Dosage 1of hMSC-Exos|Dosage 2 of hMSC-Exos|No hMSC-derived exosomes,"A Multiple, Randomized, Double-blinded, Controlled Clinical Study of Allogeneic Human Mesenchymal Stem Cell Exosomes (hMSC-Exos) Nebulized Inhalation in the Treatment of Acute Respiratory Distress Syndrome",Shanghai,Shanghai,China,"November 30, 2020"
265,266,NCT03389919,Mesenchymal Stem Cell Transplantation,Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT,MSC administration (intraosseal),EFFECTIVENESS AND SAFETY OF INTRAOSSEOUS ADMINISTRATION OF MESENCHYMAL STORMAL CELLS FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION,Moscow,,Russian Federation,"January 1, 2017"
266,267,NCT04247945,Allogeneic Hematopoietic Stem Cell Transplantation,Co-transplantation of MSC in the Setting of Allo-HSCT,Cotransplant with MSCs,Co-transplantation of Mesenchymal Stromal Cells in Allogeneic Hematopoietic Stem Cell Transplantation,Fuzhou,Fujian,China,"February 1, 2020"
267,268,NCT01297972,Aplastic Anemia,Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia,Intravenous bone marrow mesenchymal stem cells infusion,Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia,Ribeirão Preto,São Paulo,Brazil,February 2011
268,269,NCT03609905,Ulcerative Colitis (UC),Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis,Adipose-cord mesenchymal stromal cells (A-MSCs)|Conventional drugs,"A Phase I/II Randomized, Controlled, Clinical Trial for Assessment of the Safety and Efficacy of Allogeneic Adipose Mesenchymal Stem Cells in Moderate to Severe Ulcerative Colitis Patients",Liaocheng,Shandong,China,"July 1, 2018"
269,270,NCT02408432,Cardiomyopathy|Heart Failure,Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines,Laboratory Biomarker Analysis|Standard of Care|Mesenchymal Stem Cell Transplantation,Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy,Houston,Texas,United States,"January 11, 2016"
270,271,NCT04461925,COVID-19 Pneumonia,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Antibiotics|Hormones|Anticoagulant Therapy|Оxygen therapy,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord,Kyiv,,Ukraine,"May 2, 2020"
271,272,NCT03337243,Knee Osteoarthritis|Knee Pain Chronic|Joint Disease|Arthritis|Osteo Arthritis Knee|Musculoskeletal Disease,Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis,HAM and HUMCWJ Injections,Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis,Pittsburgh,Pennsylvania,United States,"November 9, 2017"
272,273,NCT04549285,Multisystem Inflammatory Syndrome in Children,Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome,Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs),A Phase I Pilot Study of the Safety of Infusions of Allogeneic Human Cord Tissue Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome in Children (MIS-C),Atlanta|Westchester|Durham,Georgia|New York|North Carolina,United States|United States|United States,"March 12, 2021"
273,274,NCT01091701,Stroke,Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke,Ex vivo cultured adult allogenic MSCs|Plasmalyte-A,"A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase -I/ II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells In Patients With Ischemic Cerebral Stroke","Jalan Hospital, 30990,|Jalan Pahang, 50586|Jalan Mufti Haji Khalil, 75400|Prai|Jalan Hospital, 47000|Km 6 Jalan Langgar, 5460 Alor Setar, Kedah","Ipoh, Perak|Kuala Lumpur|Melaka|Pulau Pinang|Sungai Buloh, Selangor",Malaysia|Malaysia|Malaysia|Malaysia|Malaysia|Malaysia,December 2011
274,275,NCT03326505,Multiple Sclerosis,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,Umbilical cord derived Mesenchymal Stem Cells|Supervised physical therapy,The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.,Amman|Amman,,Jordan|Jordan,"September 25, 2017"
275,276,NCT04869397,Covid19,Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells,Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Placebo,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): a Randomized Phase II Controlled Clinical Trial,Montreal,Quebec,Canada,"June 14, 2021"
276,277,NCT04939337,Crohn's Disease,A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.,TH-SC01,"Study to Assess the Safety and Efficacy of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells(TH-SC01), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.",Nanjing,Jiangsu,China,"November 12, 2020"
277,278,NCT01562002,Limbus Corneae Insufficiency Syndrome,Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome,Stem Cell with Amniotic Membrane Transplant,Advanced Therapy for Ocular Surface Reconstruction. Allogenic Limbus Epithelial Stem-cell Transplant vs Bone Marrow Mesenchymal Stem-cell Transplant in Limbus Insufficiency Syndrome. Double-masked Randomized Trial,Valladolid,,Spain,March 2012
278,279,NCT04670302,Supraspinatus Tear,Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation,Tendon repair procedure|Tendon repair augmented with AAdMSC-HAM composite,The Efficacy of Using Allogeneic Adipose-derived Mesenchymal Stem Cells and Human Amniotic Membrane (AAdMSC-HAM) Composite for Supraspinatus Tendon Repair Augmentation,Surabaya,East Java,Indonesia,"October 17, 2019"
279,280,NCT03174587,Lupus Nephritis,Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis,allogenic bone marrow derived mesenchymal stem cells,A Phase 1 Study to Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis.,Seoul,,"Korea, Republic of","May 30, 2017"
280,281,NCT02846883,Abdominal Aortic Aneurysm,Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms,MSCs|MSCs|Placebo,Mesenchymal Stem Cells Induce Regulatory T Cells in Patients With Aortic Aneurysm,Indianapolis,Indiana,United States,"December 5, 2016"
281,282,NCT05176366,Ulcerative Colitis,Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis,ExoFlo,"A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Ulcerative Colitis",,,,"December 1, 2022"
282,283,NCT05553132,Cartilage Defect,A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects,Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier,Hip RECLAIM: A Phase I Safety and Feasibility Trial of REcycled CartiLage Auto/Allo IMplantation for the Treatment and Repair of Focal Hip Cartilage Defects,Rochester,Minnesota,United States,October 2022
283,284,NCT04939077,"Myocardial Ischemia|Ventricular Dysfunction, Left",Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC),Allogeneic Human Umbilical Cord Mesenchymal Stem Cells,Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC),Shanghai,Shanghai,China,"November 27, 2019"
284,285,NCT02382874,Focal Segmental Glomerulosclerosis,Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis),Intravenous injection,"Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical Trial",Tehran,,"Iran, Islamic Republic of",May 2015
285,286,NCT02328612,Sepsis,"Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers",Intravenous infusion of cells,"Phase I, Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers",Amsterdam,,Netherlands,October 2014
286,287,NCT01605383,Avascular Necrosis of Femur Head,Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head,XCEL-MT-OSTEO-ALPHA|Standard treatment,"A Pilot Clinical Trial of ""ex Vivo"" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head",Barcelona,,Spain,"May 5, 2015"
287,288,NCT04362189,COVID-19,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,HB-adMSC|Placebo,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",Houston|Houston,Texas|Texas,United States|United States,"June 30, 2020"
288,289,NCT00603330,Graft-versus-host Disease|Poor Graft Function|Low Donor T-cell Chimerism,Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function,Mesenchymal stem cells,Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study,Edeghem|Brussels|Brussels|Brussels|Leuven|Gent|Haine St Paul|Yvoir|Brugge|Antwerpen|Liege|Maastricht,Antwerpen|Brabant|Brabant|Brabant|Flamish Brabant|Flanders Ost|Hainaut|Namur|West Flanders|Limburg,Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Netherlands,January 2008
289,290,NCT04995081,Parkinson Disease,Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD),Biological/Vaccine: Allogeneic HB-adMSCs|Placebo,"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease",Sugar Land,Texas,United States,"July 16, 2021"
290,291,NCT03860155,Acute-On-Chronic Liver Failure,Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure,allo-APZ2-ACLF,"An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF)",Dresden|Essen|Frankfurt|Magdeburg|Mannheim,,Germany|Germany|Germany|Germany|Germany,"March 22, 2019"
291,292,NCT04040348,Alzheimer Disease,Alzheimer's Disease Stem Cells Multiple Infusions,Approximately 100 million cells allogeneic hMSC,"A Phase I, Prospective, Open-label Trial to Evaluate the Safety, Tolerability and Exploratory Outcomes of Multiple Allogeneic Human Mesenchymal Stem Cells (HMSC) Infusions in Patients With Mild to Moderate Alzheimer's Disease",Miami,Florida,United States,"October 8, 2019"
292,293,NCT05464381,Epidermolysis Bullosa,"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)",allo-APZ2-OTS|Placebo,"A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)",,,,December 2022
293,294,NCT02241018,Acute Graft-versus-host Disease,MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD,CD25 monoclonal antibody|calcineurin inhibitors|MSCs,Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation,Guangzhou,Guangdong,China,September 2014
294,295,NCT03058068,Cystic Fibrosis,Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis,Allo-hMSCs|Placebo,"A Phase I, Randomized and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis - HAPI",,,,December 2020
295,296,NCT05521672,Stenosis; Bowel|Crohn Disease,Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease,Adipose derived allogenic mesenchymal stem cells (adAMSC),Clinical Trial Phase IIa to Evaluate the Safety and Effectiveness of Treatment With Fat-derived Mesenchymal Allogenic Mesenchymal Troncal Cells in Patients With Single Inflammatory Stenosis in the Context of Crohn's Disease.,Barcelona|Madrid|Valencia,,Spain|Spain|Spain,September 2022
296,297,NCT05559801,Osteogenesis Imperfecta|Osteogenesis Imperfecta Type III,Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI),Bone marrow-derived mesenchymal stromal cells (MSCs),A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI),,,,October 2022
297,298,NCT02585622,Diabetic Kidney Disease,NEPHSTROM for Diabetic Kidney Disease,Mesenchymal Stromal Cells|Placebo,Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study),Galway|Bergamo|Belfast|Birmingham,BG,Ireland|Italy|United Kingdom|United Kingdom,"December 11, 2017"
298,299,NCT02829216,Abnormal Hematopoiesis|Allogenic Disease|Graft vs Host Disease,Graft-versus-host Disease Associated Myelosuppression,,Functional Profiling of the Hematopoietic Stem Cell Niche in Graft Versus Host Disease Mediated Bone Marrow Insufficiency,Dresden,,Germany,April 2016
299,300,NCT01589549,Acute GVH Disease,Mesenchymal Stromal Cells for Acute Graft Versus Host Disease,Mesenchymal stromal cell therapy,A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation,Perth,Western Australia,Australia,April 2012
300,301,NCT01549665,Graft-Versus-Host Disease|GVHD|Allogeneic Hematopoietic Transplant|Disorder Related to Transplantation,Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease,Human umbilical cord blood-derived mesenchymal stem cells,Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease,Seoul,,"Korea, Republic of",January 2012
301,302,NCT02563340,Kidney Transplantation,Effect of BM-MSCs on Chronic AMR After Kidney Transplantation,"BM-MSCs|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)",Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study,Guangzhou,Guangdong,China,November 2015
302,303,NCT02563366,Kidney Transplantation|Acute Kidney Tubular Necrosis,Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.,BM-MSCs|Saline,Effect of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Recovery of Poor Early Graft Function Post Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial,Guangzhou,Guangdong,China,November 2015
303,304,NCT03798353,Myocardial Infarction,Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue,PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|Surgery by sternotomy,Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue (The PERISCOPE Trial),Badalona,Barcelona,Spain,"May 13, 2019"
304,305,NCT04034316,Nephrotic Syndrome in Children|Steroid-Dependent Nephrotic Syndrome|Idiopathic Nephrotic Syndrome,Reduce Immunosuppression With Atmp in NS ChildrEn,Cord-blood mesenchymal stromal cells,A Phase 2 Open-label Study to Evaluate the Efficacy of Allogeneic Human Cord Blood-derived Mesenchymal Stromal Cells in Maintaining Remission After Immunosuppressive Therapy Withdrawal in Pediatric Patients With Steroid-dependent Nephrotic Syndrome,Milan,MI,Italy,"November 2, 2018"
305,306,NCT02709343,Chronic Lung Allograft Dysfunction (CLAD),Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction,Bone-marrow derived MSCs|Placebo,Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD),Sydney|Brisbane|Adelaide|Melbourne|Murdoch,New South Wales|Queensland|South Australia|Victoria|Western Australia,Australia|Australia|Australia|Australia|Australia,"April 21, 2017"
306,307,NCT02290041,Discordant Immunological Response in HIV Infected Subjects,Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response,Infusion of MSC|Infusion of placebo,"Clinical Trial Phase I/II, of Test of Concept, Blind Double, Randomized, Controlled With Placebo, to Assess the Safety and Efficiency of the Treatment With Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue Expanded, in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response",Seville,,Spain,"February 8, 2017"
307,308,NCT01741857,Systemic Lupus Erythematosus,Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus,human umbilical cord derived MSC transplantation for SLE,Phase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus Erythematosus,Nanjing,Jiangsu,China,January 2012
308,309,NCT04971161,Skin Ulcer Venous Stasis Chronic,Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb),allo-APZ2-CVU|Placebo,"A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)",Augsburg|Bad Bentheim|Berlin|Berlin|Berlin|Bochum|Bochum|Braunschweig|Bremerhaven|Dresden|Dresden|Düsseldorf|Erlangen|Essen|Freiburg|Gelsenkirchen|Gera|Halle|Hamburg|Hanau|Karlsbad|Kiel|Krefeld|Langenau|Leipzig|Leipzig|Ludwigshafen|Memmingen|München|München|Münster|Nürnberg|Potsdam|Regensburg|Rostock|Schwerin|Stuttgart|Tübingen|Wuppertal|Würzburg,,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,"August 18, 2021"
309,310,NCT02240992,"Stem Cell Transplantation, Hematopoietic|Poor Graft Function|Delayed Platelet Engraftment|Hematological Diseases",MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment,PBSC|MSCs,Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant,Guangzhou,Guangdong,China,September 2014
310,311,NCT04758533,"Diffuse Intrinsic Pontine Glioma|Medulloblastoma, Childhood, Recurrent",Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy,AloCELYVIR,"Phase IB Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AloCELYVIR (Mesenchymal Allogenic Cells + ICOVIR-5) in Children, Adolescent and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Relapse/Progression in Monotherapy",Madrid,,Spain,"April 19, 2021"
311,312,NCT02104713,Skin Burn Degree Second,Stem Cell Therapy to Improve Burn Wound Healing,Allogeneic (MSC's) Application to the Burn Wounds,A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds,Miami,Florida,United States,"June 4, 2014"
312,313,NCT00883727,Myocardial Infarction,Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI,Stem cell|Plasmalyte A,"A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intravenous ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With st Elevated Acute Myocardial Infarction (Stemi)",Hyderabad|Ahmedabad|Bangalore|Bangalore,Andhra Pradesh|Gujarat|Karnataka|Karnataka,India|India|India|India,April 2009
313,314,NCT04623606,Osteogenesis Imperfecta,Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones,BOOST cells,"Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls",Vellore,Tamil Nadu,India,"May 20, 2019"
314,315,NCT00314483,Graft vs Host Disease,Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease,Mesenchymal Stem Cell Infusion,Evaluation of Potential Mesenchymal Stem Cells for the Treatment of Graft Versus Host Disease Following an Allogeneic Stem Cell Transplant,Vellore,Tamil Nadu,India,June 2007
315,316,NCT03706482,Osteogenesis Imperfecta,Boost Brittle Bones Before Birth,BOOST cells,"An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Efficacy of Postnatal or Prenatal and Postnatal Intravenous Administration of Allogeneic Expanded Fetal Mesenchymal Stem Cells for the Treatment of Severe Osteogenesis Imperfecta Compared With a Combination of Historical and Untreated Prospective Controls",Stockholm,,Sweden,"August 12, 2019"
316,317,NCT01922908,Ischemic Stroke,Mesenchymal Stromal Cells for Ischemic Stroke,MSC Infusion|Placebo Comparator,SAfety of Mesenchymal Stromal Cells for Ischemic Stroke,,,,December 2016
317,318,NCT04527224,Covid19 Pneumonia,Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia,AstroStem-V,A Phase I/Ⅱa Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia,Phoenix|Dallas,Arizona|Texas,United States|United States,"October 1, 2022"
318,319,NCT04388982,Alzheimer Disease,the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease,low dosage MSCs-Exos administrated for nasal drip|mild dosage MSCs-Exos administrated for nasal drip|high dosage MSCs-Exos administrated for nasal drip,"Open-Label, Single-Center, Phase I/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in Patients With Mild to Moderate Dementia Due to Alzheimer's Disease",Shanghai,Shanghai,China,"July 1, 2020"
319,320,NCT04410731,Facet-Mediated Low Back Pain,Allogeneic BM-MSCs in Patients With Lumbar Facet Arthropathy,Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy,"CellKine: Phase I Study Evaluating the Safety and Feasibility of Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells in Subjects With Painful Lumbar Facet Joint Arthropathy",Jacksonville,Florida,United States,"April 28, 2020"
320,321,NCT04497805,Diabetic Foot Ulcer,Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers,ALLO-ASC-SHEET,A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers,Los Angeles,California,United States,"August 1, 2020"
321,322,NCT04835883,Systemic Lupus Erythematosus,Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients,CS20AT04 (allogenic bone marrow derived mesenchymal stem cell),"Open-label, Single-arm, 24-week Investigator Study to Evaluate the Efficacy and Safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) Administered in Patients With Lupus Nephritis or Lupus Cytopenia",Seoul,,"Korea, Republic of","September 26, 2019"
322,323,NCT05035862,Asthma,Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma,Albuterol Sulfate|Interferon gamma-primed mesenchymal stromal cells (MSCs)|Prednisone,"A Phase 1 Study to Evaluate Safety, Toxicity, and Potential Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma",Atlanta,Georgia,United States,"March 16, 2022"
323,324,NCT04615429,Acute Respiratory Distress Syndrome|COVID-19 Pneumonia,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Mesenchymal stromal cells|Placebo,"Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19",Majadahonda,Madrid,Spain,"September 15, 2020"
324,325,NCT03392311,Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity,Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis,Calcipotriol ointment|adipose-derived multipotent mesenchymal stem cells,Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis,Guangzhou,Guangdong,China,"August 17, 2019"
325,326,NCT04494386,Covid19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Umbilical Cord Lining Stem Cells (ULSC)|Placebo (carrier control),Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19,Miami|Sioux Falls,Florida|South Dakota,United States|United States,"July 23, 2020"
326,327,NCT02484560,Duchenne Muscular Dystrophy,Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2,Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell,Efficacy of Allogenic Mesenchymal Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2,Gaziantep,,Turkey,June 2015
327,328,NCT00515307,"Hypercholesterolemia, Familial",Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia,Cellular transplantation,In-Vitro Transdifferentiation of Mesenchymal Stem Cells to Hepatocytes and Allogenic Transplantation of Hepatocytes to the Patients With Homozygous Familial Hypercholesterolemia,Tehran,,"Iran, Islamic Republic of",June 2007
328,329,NCT03484741,Type 1 Diabetes Mellitus,Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients,MSC and PRP,A Preliminary Safety and Efficacy Evaluation of Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Mellitus (T1DM) Patients,Ho Chi Minh City,Ho Chi Minh,Vietnam,"April 1, 2017"
329,330,NCT04281797,Transplantation Infection|Kidney Transplant; Complications|Stem Cell Transplant Complications|Liver Transplant; Complications|Microbial Colonization,Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients,Intestinal microbiome new generation sequencing,"Intestinal Microbiome Composition Dynamics Over the Course of Kidney Transplantation, Liver Transplantation, Allogeneic Hematopoietic Stem Cells and Mesenchymal Stem Cells Transplantation",Minsk,,Belarus,"January 1, 2020"
330,331,NCT02582775,Epidermolysis Bullosa,MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs,Thymoglobulin|Cyclophosphamide|Fludarabine|Total Body Irradiation|Bone marrow infusion|Tacrolimus|Mycophenolate Mofetil|Donor mesenchymal stem cell infusions|Busulfan,MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions,Minneapolis,Minnesota,United States,March 2016
331,332,NCT05456243,Kidney Transplant,Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients,Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|High dose adipose tissue derived mesenchymal stromal cells (A-MSC),Safety of Intraarterial Infusion of Adipose Tissue-derived Mesenchymal Stromal Cells to Treat Antibody-mediated and Cellular Rejection in Adult Kidney Transplant Recipients (AMSCAR),Rochester,Minnesota,United States,October 2022
332,333,NCT02635464,Chronic Ischemic Cardiomyopathy,Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy,hUC-MSCs+Injectable collagen scaffold+CABG|hUC-MSCs+CABG|CABG,The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (hUC-MSCs) With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy,Nanjing,Jiangsu,China,October 2015
333,334,NCT00136903,Graft Vs Host Disease,Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD),Prochymal® - 2 Million cells/kg|Prochymal®- 8 Million cells/kg|Methylprednisolone|Prednisone|Cyclosporine|Tacrolimus|Mycophenolate Mofetil,"A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation",Indianapolis|Kansas City|Hackensack|Buffalo|New York|Rochester|Valhalla|Houston|Milwaukee,Indiana|Missouri|New Jersey|New York|New York|New York|New York|Texas|Wisconsin,United States|United States|United States|United States|United States|United States|United States|United States|United States,"April 27, 2005"
334,335,NCT04276987,Coronavirus,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,MSCs-derived exosomes,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Shanghai,Shanghai,China,"February 15, 2020"
335,336,NCT03943576,Knee Osteoarthritis,Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis,GXCPC1|HA,Adipose-Derived Stem Cells (ADSCs) Injections for Knee Osteoarthritis,Hsinchu,,Taiwan,"December 1, 2019"
336,337,NCT04501341,T2D,BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients,"Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Intravenous Infusion of UC-MSC","Effectivity and Safety of Autologous BM-MNC Stem Cell Therapy and Allogenic Umbilical Cord Mesenchymal Stem Cell for Type 2 Diabetes Mellitus Patients""",Jakarta Pusat,DKI Jakarta,Indonesia,"March 14, 2016"
337,338,NCT02962661,Cardiomyopathy|Heart Failure|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines,Best Practice|Laboratory Biomarker Analysis|Mesenchymal Stem Cell Transplantation|Mesenchymal Stem Cell Transplantation,Randomized 3-Arm Trial With Standard of Care Alone vs Either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Plus Standard of Care in Patients With Anthracycline-Associated Cardiomyopathy,Houston,Texas,United States,"July 18, 2020"
338,339,NCT03529877,Recessive Dystrophic Epidermolysis Bullosa,Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa,allo-APZ2-EB,"An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)",Minneapolis|Salzburg|Paris|Freiburg|London|London,Minnesota,United States|Austria|France|Germany|United Kingdom|United Kingdom,"January 16, 2019"
339,340,NCT05407766,Rectal Fistula,Mesenchymal Stem Cells (MSCs) for Perianal Fistula,OSSM-001|Placebo,A Phase I Safety Study of Allogeneic Bone Marrow Derived MSCs for Refractory Perianal Fistulizing Crohn's Disease,,,,August 2022
340,341,NCT03672825,Cartilage Defect,REcycled CartiLage Auto/Allo IMplantation,REcycled CartiLage Auto/Allo IMplantation,RECLAIM: A Phase I Safety and Feasibility Trial of REcycled CartiLage Auto/Allo IMplantation for the Treatment and Repair of Focal Knee Cartilage Defects,Rochester,Minnesota,United States,"September 13, 2018"
341,342,NCT03684122,Parkinson Disease,Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).,Injection of Umbilical cord derived MSCs,A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).,Amman,,Jordan,"June 1, 2018"
342,343,NCT01844063,Liver Failure,Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure,Conventional plus BM-MSC treatment|Conventional plus UC-MSC treatment|Conventional treatment,Clinical Comparison of Safety and Efficacy of Allogeneic Umbilical-Cord and Bone Marrow-derived Mesenchymal Stem Cells Transplantation for HBV-related Liver Failure,Guangzhou,Guangdong,China,July 2013
343,344,NCT03726255,Perianal Fistula,Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula,Mesenchymal Stem Cell injection,Retrospective Evaluation of Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula.,Madrid,,Spain,"April 1, 2014"
344,345,NCT01686139,Type I Diabetes Mellitus With Ulcer|Type II Diabetes Mellitus With Ulcer,Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers,ABMD-MSC,Phase 1 Study: Treatment of Patients With Diabetic Foot Complications With Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC),Ramat Gan,,Israel,March 2016
345,346,NCT04377334,ARDS|COVID-19,Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS),MSC,Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS,Tuebingen,,Germany,May 2022
346,347,NCT01061099,Osteogenesis Imperfecta Type II|Osteogenesis Imperfecta Type III,Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta,Mesenchymal Stromal Cells,A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta,Philadelphia,Pennsylvania,United States,February 2010
347,348,NCT02917291,Acute Traumatic Spinal Cord Injury,Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury,FAB117-HC|Control group|FAB117-HC,"Clinical Trial of Phase 1/2 to Evaluate the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of FAB117-HC, a Drug Whose Active Ingredient is HC016, Allogeneic Adipose Derived Adult Mesenchymal Stem Cells Expanded and Pulsed With H2O2, in Acute Traumatic SCI Patients.",A Coruña|Barcelona|Granada|Madrid|Sevilla|Toledo|Valencia|Zaragoza|Zaragoza,,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,December 2016
348,349,NCT04544215,Drug-resistant,A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection,Dosage 1 of MPCs-derived exosomes|Dosage 2 of MPCs-derived exosomes|No MPCs-derived exosomes,A Clinical Study of Allogeneic Human Adipose-derived Mesenchymal Progenitor Cell Exosomes (haMPC-Exos) Nebulizer for the Treatment of Carbapenem-resistant Gram-negative Bacilli-induced Pulmonary Infection,Shanghai,Shanghai,China,"July 1, 2020"
349,350,NCT02561767,Kidney Transplantation|Acute Kidney Tubular Necrosis,Effect of BM-MSCs in DCD Kidney Transplantation,bone marrow-derived mesenchymal stem cells|Saline|Induction therapy (ATG or Basiliximab)|Maintenance therapy (Low-dose CNI + MPA + steroids),The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial,Guangzhou,Guangdong,China,October 2015
350,351,NCT03173638,Non Arteritic Ischemic Optic Neuropathy,Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy,intravitreal injection of MSV,Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION),Valladolid,,Spain,"March 23, 2018"
351,352,NCT01941394,Graft-versus-host Disease|Relapse,Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation,Mesenchymal stem cells,Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation,Moscow,,Russian Federation,October 2007
352,353,NCT03920397,Type 1 Diabetes Mellitus,Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus,Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation,Allogenic Adipose Derived Mesenchymal Stem Cells and Vitamin D Supplementation in Patients With Recent-onset Type 1 Diabetes Mellitus,Rio de Janeiro,,Brazil,"March 1, 2015"
353,354,NCT05126563,Post COVID-19 Syndrome,Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome,HB-adMSCs (allogeneic)|Placebo,"A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.",Sugar Land,Texas,United States,"January 6, 2022"
354,355,NCT01033552,Epidermolysis Bullosa,"Biochemical Correction of Severe EB by Allo HSCT and ""Off-the-shelf"" MSCs",Cyclophosphamide|Fludarabine|Anti-thymocyte globulin|Cyclosporine A|Mycophenolate mofetil|Mesenchymal stem cell transplantation|Total body irradiation|Bone marrow or umbilical cord blood (UCG) stem cell transplantation,"MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and ""Off-the-shelf"" Mesenchymal Stem Cells",Minneapolis,Minnesota,United States,January 2010
355,356,NCT04434768,Acute Stroke,Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke,UMSC01,"A Phase I, Open Label Study to Evaluate the Safety and to Explore the Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Ischemic Stroke",Taichung|Taipei City,Non-US,Taiwan|Taiwan,"May 5, 2020"
356,357,NCT01045382,"Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute|Leukemia, Myelocytic, Chronic|Myeloproliferative Disorders|Myelodysplastic Syndromes|Multiple Myeloma|Leukemia, Lymphocytic, Chronic|Hodgkin's Disease|Lymphoma, Non-Hodgkin",MSC and HSC Coinfusion in Mismatched Minitransplants,Mesenchymal stem cells|Isotonic solution,Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study,Edeghem|Brussels|Leuven|Gent|Brugge|Yvoir|Antwerpen|Brussels|Brussels|Liège,Antwerpen|Brabant|Flamish Brabant|Flanders Ost|Flanders West|Namur,Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium,July 2010
357,358,NCT02083731,"Stem Cell Transplantation, Hematopoietic|CMV Infection|Hematological Diseases",MSC for Treatment of CMV Infection,MSCs,Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant,Guangzhou,Guangdong,China,January 2014
358,359,NCT01443689,Burns,Allogenic Stem Cell Therapy in Patients With Acute Burn,human umbilical cord mesenchymal stem cells|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Conventional therapy,A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn,Kunming,Yunnan,China,July 2011
359,360,NCT04661644,Critical Limb Ischemia,Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia,Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial),A Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia,Seoul,,"Korea, Republic of","November 4, 2020"
360,361,NCT05345418,Sexual Dysfunction Male,Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency,Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency,Evaluation of the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency: A Phase I/IIa Randomised Crossover Trial,Hanoi,,Vietnam,"June 1, 2022"
361,362,NCT03943940,Type 2 Diabetes Mellitus,BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients,BM-MNC and UC-MSC|Control,A Preliminary Safety and Efficacy Evaluation of Bone Marrow Mononuclear Cells (BM-MNCs) and Umbilical Cord Tissue-derived Mesenchymal Stem Cells (UC-MSC) Infusion for Type 2 Diabetes Mellitus (T2DM) Patients,Ho Chi Minh City,Ho Chi Minh,Vietnam,"April 24, 2019"
362,363,NCT04499105,Degenerative Disc Disease|Low Back Pain|Disc Degeneration,Effectiveness and Safety of Mesenchymal Stem Cell (MSC) Implantation on Degenerative Discus Disease Patients,"Mesenchymal Stem Cell + NaCl 0,9% 2ml",Effectiveness and Safety of Allogenic Mesenchymal Stem Cell (MSC) Implantation on Degenerative Discus Disease Patients (Clinical Trial),Jakarta Pusat,DKI Jakarta,Indonesia,"July 24, 2017"
363,364,NCT02270307,Leukemia|Multiple Myeloma,MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis,Cyclophosphamide|Mesenchymal stromal cells,Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis,Moscow,,Russian Federation,January 2014
364,365,NCT00883870,Critical Limb Ischemia,Mesenchymal Stem Cells in Critical Limb Ischemia,mesenchymal stem cells|Plasmalyte A,"A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)",Bangalore|Bangalore|Kochi|New Delhi,Karnataka|Karnataka|Kerala,India|India|India|India,April 2009
365,366,NCT04445220,COVID-19|Acute Kidney Injury|Sepsis,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,SBI-101,"A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy",Albuquerque|Charleston,New Mexico|South Carolina,United States|United States,"November 19, 2020"
366,367,NCT02481440,Spinal Cord Injuries,Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI,human umbilical cord mesenchymal stem cells (hUC-MSCs),Repeated Subarachnoid Administrations of Human Umbilical Cord Mesenchymal Stem Cells in Treating Spinal Cord Injury,Guangzhou,Guangdong,China,"March 30, 2018"
367,368,NCT02034188,Multiple Sclerosis,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,Umbilical cord mesenchymal stem cells,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,Panama City,,Panama,January 2014
368,369,NCT01985464,Rheumatoid Arthritis,Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis,Umbilical cord mesenchymal stem cells,Feasibility Study of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UC-MSC) in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis,Panama City,,Panama,October 2013
369,370,NCT04457609,COVID|Pulmonary Infection|Sars-CoV2,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Oseltamivir|Azithromycin|Umbilical Cord Mesenchymal Stem Cells,Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Jakarta Pusat|Jakarta|Jakarta|Depok,DKI Jakarta|DKI Jakarta|DKI Jakarta|West Java,Indonesia|Indonesia|Indonesia|Indonesia,July 2020
370,371,NCT04629833,Steroid-refractory Acute Graft-versus-host Disease,Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy,MC0518|BAT,"A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)",Grenoble|Lille|Nice|Pierre Benite Cedex|Rennes|Toulouse|Vandoeuvre les Nancy|Munich|Würzburg|Frankfurt am Main|Hannover|Münster|Essen|Koeln|Dresden|Leipzig|Jena|Jena|Berlin|Bonn|Essen|Frankfurt|Freiburg|Mainz|Mannheim|Tuebingen|Wrocław|Barcelona|Barcelona|Barcelona|Barcelona|Barcelona|Madrid|Madrid|Valencia|Huddinge,Bavaria|Bavaria|Hessen|Niedersachsen|Nordrhein-Westfalen|North Rhine-Westphalia|North Rhine-Westphalia|Sachsen|Saxony|Thüringen|Thüringen|Dolnoslaskie,France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Poland|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden,"August 16, 2021"
371,372,NCT02237846,Osteoarthritis of the Knee,Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis,Human umbilical cord tissue-derived mesenchymal stem cells,Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis,Panama City,,Panama,September 2014
372,373,NCT04919135,Frailty,Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty,Umbilical Cord Mesenchymal Stem Cells transplantation|standard frailty treatment and supplementary medication,Clinical Study of Mesenchymal Stem/Stromal Cell Therapy in Frailty: a Proposed Experimental Design for Therapeutic and Mechanism Investigation,,,,"July 1, 2021"
373,374,NCT04903327,Covid19,Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress,COVI-MSC|Placebo,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Salvador|Salvador|Campinas|Jaú|São Bernardo Do Campo|São Paulo,BA|BA|SP|SP|SP|SP,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,"November 16, 2021"
374,375,NCT05204329,Mesenchymal Stromal Cells|Cornea|Corneal Defect|Corneal Epithelium Defect,Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease,MSC Secretome Eye Drops,Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease,,,,"December 1, 2022"
375,376,NCT03015623,Acute Kidney Injury,A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy,SBI-101|Sham,"A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy",Allentown,Pennsylvania,United States,"June 20, 2017"
376,377,NCT03964922,"Relapse Leukemia|Allogeneic Stem Cell Transplantation|Immune Evasion, Tumor",Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation,blood sample|bone marrow sample,Study of the Immunoevasive Mecanisms and Especially Myeloid Suppressive Cells in the Medullar Microenvironment Employed by Myeloid Malignancy (AML and High Risk MDS) When Relapsing After Allogeneic Stem Cell Transplantation,,,,"September 1, 2019"
377,378,NCT05549609,Venous Leg Ulcer,A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers,XSTEM-VLU|Vehicle,"A Single-centre, Randomised, Single-blind Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of a Single Topical Dose of Allogeneic Integrin α10β1-selected Mesenchymal Stem Cells (XSTEM-VLU) in Patients With Difficult-to-heal Venous Leg Ulcers",Linköping,,Sweden,September 2022
378,379,NCT02387723,Heart Failure,CSCC_ASC Therapy in Patients With Severe Heart Failure,Allogeneic adipose derived stem cells (CSCC_ASC),Allogeneic Adipose Tissue-derived Stromal/Stem Cell Therapy in Patients With Ischemic Heart Disease and Heart Failure - a Safety Study,Copenhagen,,Denmark,December 2014
379,380,NCT04776538,Xerostomia Following Radiotherapy,Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients,Stem cells|Placebo,"A Single-centre, Double-blinded, Randomised, Placebo-controlled, Phase II Study to Investigate the Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients (MESRIX-III)",Copenhagen,,Denmark,"February 9, 2021"
380,381,NCT03169231,Aging Frailty,Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty,Longeveron Mesenchymal Stem Cells (LMSCs)|Placebo,"A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty",Aventura|Coral Gables|Fort Myers|Miami Lakes|Miami|Miami|Naples,Florida|Florida|Florida|Florida|Florida|Florida|Florida,United States|United States|United States|United States|United States|United States|United States,"July 6, 2017"
381,382,NCT03370874,Diabetic Foot Ulcer,Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.,ALLO-ASC-DFU|Vehicle sheet,"Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study",Seoul,,"Korea, Republic of","July 4, 2018"
382,383,NCT01041001,Cartilage Injury|Osteoarthritis,Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury,Cartistem|Microfracture treatment,"Randomized, Open-Label, Multi-Center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or Defect",Incheon|Incheon|Seoul|Seoul|Seoul|Seoul|Seoul|Seoul,Gyunggido,"Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of",February 2009
383,384,NCT00951210,Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia,Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI),PLX-PAD,Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.,Birmingham|Durham,Alabama|North Carolina,United States|United States,August 2009
384,385,NCT00705120,Osteogenesis Imperfecta,Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation,"Bone Marrow Cell Transplantation|Irradiation, Total Body|Cyclophosphamide|Cyclosporin|Mesenchymal Stem Cell Transplantation|Busulfan",Treatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation,Memphis,Tennessee,United States,November 1995
385,386,NCT03754465,Diabetic Foot Ulcer,Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers,ALLO-ASC-DFU|Hydrogel SHEET(Vehicle control),A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers,Los Angeles,California,United States,"January 2, 2019"
386,387,NCT02409940,Renal Transplant Rejection,To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients,Mesenchymal Stem Cells,A Randomized Trial to Elucidate Effect of Mesenchymal Stem Cells on Immune Modulation in Living Related Kidney Transplant Patients,Chandigarh,,India,September 2013
387,388,NCT03505034,Spinal Cord Injuries,Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury,Umbilical Cord Mesenchymal Stem Cells,"The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury：A Multicenter, Prospective, Cohort Study",Guangzhou,Guangdong,China,"September 1, 2019"
388,389,NCT04061746,"Diabetes Mellitus, Type 1",Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells,Mesenchymal Stem Cells (MSCs)|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin),Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells,Charleston,South Carolina,United States,"February 13, 2020"
389,390,NCT02055625,Graft -Versus-host-disease,Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease,Mesenchymal stromal cells,Treatment of Oral Mucosa in Patients With Graft-versus-host Disease Following Injection of Mesenchymal Stem Cells - Human Pilot Study,Stockholm,Huddinge,Sweden,January 2014
390,391,NCT01849887,Ischemic Stroke,Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke,bone marrow-derived mesenchymal stem cells|Placebo,Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke,Orange,California,United States,January 2016
391,392,NCT01539902,Lupus Nephritis,Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis,Human Umbilical Cord derived MSCs|Cyclophosphamide,"A Randomized, Double Blind, Parallel Group, Placebo Controlled Research of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis",Kunming,Yunan,China,February 2012
392,393,NCT03183726,Diabetic Foot Ulcer,A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial,ALLO-ASC-DFU,A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-DFU-101,,,,"January 11, 2016"
393,394,NCT03183661,Crohn Disease,A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial,ALLO-ASC-CD,Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101),,,,"November 16, 2016"
394,395,NCT03521336,Spinal Cord Injury,Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury,Umbilical Cord Mesenchymal Stem Cells|Placebo,"The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial",Guangzhou,Guangdong,China,"September 1, 2019"
395,396,NCT03521323,Spinal Cord Injuries,Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury,Umbilical Cord Mesenchymal Stem Cells|Placebos,"The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial",Guangzhou,Guangdong,China,"September 1, 2019"
396,397,NCT01392105,Acute Myocardial Infarction,Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction,Mesenchymal stem cell|Control group,"A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction",Wonju|Inchon|Seoul,Gangwon-do,"Korea, Republic of|Korea, Republic of|Korea, Republic of",March 2007
397,398,NCT03847844,Acute-graft-versus-host Disease,UCMSCs as Front-line Approach of Treatment for Patients With aGVHD,Umbilical cord derived mesenchymal stem cell|Placebo,Cytopeutics® Umbilical Cord Mesenchymal Stem Cells (Cyto-MSC) for Patients With Grade II -IV Acute Graft-Versus-Host Disease: A Phase I/II Clinical Study,Ampang,Selangor,Malaysia,"February 1, 2019"
398,399,NCT03810521,"Osteoarthritis, Knee",Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis,umbilical cord derived-mesenchymal stromal cells,A Phase I Dose-escalation Trial to Assess Safety and Efficacy of Cellistem-OA in Patients With Knee Osteoarthritis (CLT-OA1),Santiago,Xiii,Chile,"March 1, 2019"
399,400,NCT04971980,Rheumatoid Arthritis,Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis,hUC-MSC infusion (BC-U001),"A Phase 1/2a, Open-Label Study to Evaluate the Safety and Efficacy of a Single Intravenous Infusion of BC-U001, a Human Umbilical Cord-Derived Mesenchymal Stem Cell Product, for Rheumatoid Arthritis",Beijing,Beijing,China,"April 12, 2021"
400,401,NCT00919958,Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia,Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia,PLX-PAD IM injection,Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties.,Berlin,,Germany,June 2009
401,402,NCT00827398,Graft-versus-host-disease,Treatment of Steroid Resistant GVHD by Infusion MSC,MSC (hPPL),Treatment of Steroid Resistant Grade II to IV GVHD by Infusion MSCof Mesenchymal Stem Cells Expanded With Human Plasma and Platelet Lysate a Phase I/II Study,Utrecht|Utrecht,,Netherlands|Netherlands,January 2009
402,403,NCT02260375,Liver Transplant Rejection,MSC Therapy in Liver Transplantation,Mesenchymal Stromal Cells,THIRD-PARTY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVER TRANSPLANT RECIPIENTS,Bergamo|Bergamo|Bergamo|Bergamo|Bologna|Bologna,,Italy|Italy|Italy|Italy|Italy|Italy,October 2014
403,404,NCT04953663,Stroke,Clinical Plan of Ischemic Stroke,it-hMSC,"A Multicenter, Blind, Randomized, Placebo-controlled Phase I / IIA Study to Evaluate the Safety, Tolerability, and Initial Efficacy of a Single Injection of Ischemia Tolerant Human Allogeneic Bone Marrow Mesenchymal Stem Cells in Patients With Ischemic Stroke",Beijin,,China,"January 1, 2021"
404,405,NCT05075811,"Pouch, Ileal|Fistula",Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease,Ossium vBM-MSC|Placebo,A Phase IB/IIA Study of Ossium Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch,Cleveland,Ohio,United States,"February 1, 2022"
405,406,NCT01663116,Rheumatoid Arthritis Aggravated,"Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients",Stem cells|Placebo,"""Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients"".",Oviedo|Mérida|La Laguna|Barakaldo|Bilbao|A Coruña|Barcelona|Barcelona|Barcelona|Córdoba|Granada|Granada|Guadalajara|Madrid|Madrid|Madrid|Madrid|Málaga|Santander|Sevilla|Sevilla|Valencia|Valencia,Asturias|Badajoz|Tenerife|Vizcaya|Vizcaya,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,March 2011
406,407,NCT01541579,Crohn's Disease,Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease,Cx601|Saline solution,"A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.",Innsbruck|St. Veit/Glan|Wien|Genk|Gent|Leuven|Roeselare|Amiens|Bordeaux|Caen|Clichy|Lille|Marseille|Nice|Paris|Berlin|Berlin|Braunschweig|Frankfurt/Main|Köln|Lüneburg|Haifa|Jerusalem|Petah Tikva|Tel Aviv|Tel Hashomer|Bologna|Firenze|Milano|Napoli|Padova|Rome|Rome|Amsterdam|Amsterdam|Eindhoven|Utrecht|Manises|Barcelona|Cordoba|Huelva|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Palma de Mallorca|Pontevedra|Seville|Valencia|Valencia,Valencia,Austria|Austria|Austria|Belgium|Belgium|Belgium|Belgium|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Israel|Israel|Israel|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Netherlands|Netherlands|Netherlands|Netherlands|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,July 2012
407,408,NCT04093336,"Infarction, Middle Cerebral Artery|Infarction, Anterior Cerebral Artery|Cerebral Infarction|Stroke, Ischemic|Acute Stroke|Brain Infarction|Infarction, PCA|Infarction, Posterior Circulation, Brain",Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients,human umbilical cord mesenchymal stem cells|Placebo|standardized treatment,Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients,Shanghai,Shanghai,China,"January 13, 2019"
408,409,NCT05329662,Sexual Dysfunction Female,Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female,Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency,Evaluation of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Efficacy for the Treatment of Sexual Function Impairment in Female,Hanoi,,Vietnam,"November 1, 2022"
409,410,NCT02648386,Rectal Cancer|Erectile Dysfunction,Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery,Laparoscopic surgery|NeuroRegen scaffold transplantation|NeuroRegen scaffold/BMMCs transplantation|NeuroRegen scaffold/HUC-MSCs transplantation,Bone Marrow Mononuclear Cells or Human Umbilical Cord-derived Mesenchymal Stem Cells Combined With NeuroRegen Scaffold™ Transplantation for the Improvement of Erectile Function in Men After Rectal Cancer Surgery,Nanjing,Jiangsu,China,January 2016
410,411,NCT04435249,Bronchopleural Fistula,ENgineered Tissue Repair of BronchopleUral fiSTula,BPF-001,"Phase I/II, Open Label Study to Assess the Safety and Efficacy Autologous Bone Marrow-derived Mesenchymal Stromal Cells Seeded on to Decellularised Airway Scaffold in Subjects With Clinically Significant Bronchopleural Fistula",,,,October 2022
411,412,NCT02410239,Cerebral Adrenoleukodystrophy,MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD),Mesenchymal Stem Cells,MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD),,,,June 2015
412,413,NCT03219801,Systemic Lupus Erythematosus,Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus,mesenchymal stem cells,Evaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells,Shijiazhuang,Hebei,China,"August 1, 2017"
413,414,NCT02982915,Aging Frailty,Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty,Longeveron Mesenchymal Stem Cells (LMSCs)|Fluzone High Dose Vaccine,Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty,Coral Gables|Fort Myers|Miami|Miami|Baltimore|Rockville,Florida|Florida|Florida|Florida|Maryland|Maryland,United States|United States|United States|United States|United States|United States,November 2016
414,415,NCT03003364,"Spinal Cord Injury, Chronic",Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury,XCEL-UMC-BETA|Placebo,"A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury",Badalona,Barcelona,Spain,"December 27, 2016"
415,416,NCT00557635,Tibia or Femur Pseudo-arthrosis,Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow,Chirurgical procedure,Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow,,,,January 2008
416,417,NCT04961658,Septic Shock,Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients,GEM00220,Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients,Oshawa|Toronto,Ontario|Ontario,Canada|Canada,"August 11, 2021"
417,418,NCT00988338,"Tibiotalar Arthrodesis|Subtalar Arthrodesis|Calcaneocuboid Arthrodesis|Talonavicular Arthrodesis|Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular)|Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)",Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion,Trinity Evolution,"A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution Matrix) in Subjects Undergoing Foot and Ankle Fusion",Hollywood|Baltimore|Albuquerque|Charlotte|Durham|Upper Arlington|Pittsburgh|State College|Sparta|Burien,Florida|Maryland|New Mexico|North Carolina|North Carolina|Ohio|Pennsylvania|Pennsylvania|Tennessee|Washington,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,September 2009
418,419,NCT01602328,Acute Kidney Injury,A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects,AC607|Vehicle Only,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects",Birmingham|San Diego|Stanford|Washington|Chicago|Portland|Baltimore|Boston|Boston|Detroit|Rochester|New Brunswick|New York|Durham|Columbus|Wynnewood|Houston|Burlington|Charlottesville|Seattle|Charleston|Calgary|Edmonton|Winnipeg|Halifax|Hamilton|London|Toronto|Toronto|Montreal|Quebec,Alabama|California|California|District of Columbia|Illinois|Maine|Maryland|Massachusetts|Massachusetts|Michigan|Minnesota|New Jersey|New York|North Carolina|Ohio|Pennsylvania|Texas|Vermont|Virginia|Washington|West Virginia|Alberta|Alberta|Manitoba|Nova Scotia|Ontario|Ontario|Ontario|Ontario|Quebec,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,June 2012
419,420,NCT02359929,Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease,BMT Autologous MSCs for GvHD,Autologous mesenchymal stromal cells (MSCs),A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft Versus Host Disease,Atlanta,Georgia,United States,January 2015
420,421,NCT02336230,Grade B aGVHD|Grade C aGVHD|Grade D aGVHD,"A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)",remestemcel-L,"A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD",Los Angeles|Orange|San Francisco|Aurora|Wilmington|Miami|Chicago|Detroit|Jackson|Saint Louis|New York|New York|New York|Durham|Portland|Charleston|San Antonio|Richmond|Seattle|Milwaukee,California|California|California|Colorado|Delaware|Florida|Illinois|Michigan|Mississippi|Missouri|New York|New York|New York|North Carolina|Oregon|South Carolina|Texas|Virginia|Washington|Wisconsin,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,"June 4, 2015"
421,422,NCT02483364,Pseudoarthrosis,A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure),HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment),A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) and HC-SVT-1002 (Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones,Esplugues de Llobregat,Barcelone,Spain,"November 10, 2015"
422,423,NCT05210309,"Safety|Efficacy, Self",National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study),Stem Cell Therapy,National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study),Elche|Vigo|Barcelona|Valencia,Alicante|Pontevedra,Spain|Spain|Spain|Spain,"January 1, 2020"
423,424,NCT04896853,COVID-19 Acute Respiratory Distress Syndrome,Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®,ProTrans®,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial,Örebro,,Sweden,"May 18, 2021"
424,425,NCT03267784,Diabetic Neuropathic Ulcer,"Allogeneic ABCB5-positive Stem Cells for Treatment of DFU ""Malum Perforans""",allo-APZ2-DFU,"An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-DFU on Wound Healing of Diabetic Neuropathic Ulcer (DFU)",Greifswald|Heidelberg|Kassel|Kronshagen|Leipzig|Ludwigshafen|Würzburg,,Germany|Germany|Germany|Germany|Germany|Germany|Germany,"November 21, 2017"
425,426,NCT03631589,Steroid-resistant Severe aGVHD,MSC for Severe aGVHD,MSCs,Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells,Fuzhou,Fujian,China,"December 1, 2017"
426,427,NCT02706132,Liver Transplantation,Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation,Mesenchymal Stem Cells(MSCs),MSC for ABO Incompatible Liver Transplantation,Guangzhou,Guangdong,China,February 2014
427,428,NCT04194671,Acute Kidney Injury|Mesenchymal Stem Cells,Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury,Mesenchymal stem cells|Saline,"A Single-center, Randomized, Placebo-controlled, Patient-blinded Study of Mesenchymal Stem Cells Therapy in Subjects With Severe Acute Kidney Injury Receiving Routine Therapy",Beijing,Beijing,China,"December 31, 2021"
428,429,NCT03166865,Osteoarthritis of the Knee,Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis,Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Hyaluronic acid,Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis,Liaocheng,Shandong,China,"October 1, 2018"
429,430,NCT02381366,Bronchopulmonary Dysplasia,Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study,Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,"A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)",Chicago,Illinois,United States,March 2015
430,431,NCT05443464,"GVHD,Acute",Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD),OSSM-001,A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease,,,,"June 5, 2023"
431,432,NCT01489267,Hereditary Cerebellar Ataxia.,A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation,stem cell transplantation,The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients,Beijing,,China,December 2011
432,433,NCT02854579,Hypoxic-Ischemic Encephalopathy,Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy,neural progenitor cell|Paracrine factors|progenitor cell and paracrine factors,Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy,Beijing|Beijing,Beijing,China|China,January 2013
433,434,NCT01739777,Dilated Cardiomyopathy,Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy,ucMSC|Controls,"Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology",Santiago de Chile,,Chile,December 2012
434,435,NCT04011059,Cardiovascular Diseases|Heart Failure|Coronary Artery Disease|Mesenchymal Stem Cell Transplantation|Regenerative Medicine,Randomized Study of Coronary Revascularization Surgery With Injection of WJ-MSCs and Placement of an Epicardial Extracellular Matrix,Wharton's jelly-derived mesenchymal cells,Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton's Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy,Medellín,Antioquia,Colombia,"July 2, 2019"
435,436,NCT02379442,Graft-Versus-Host Disease,Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids,MSC,A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers,Bethesda,Maryland,United States,"February 23, 2015"
436,437,NCT01754454,Acute GVH Disease,Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease,Human Umbilical Cord Derived MSC,"Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Acute Graft-versus-host Disease",Beijing|Beijing,,China|China,December 2012
437,438,NCT05292625,Ischemic Stroke,Stem Cell Infusion in the Treatment of Patients With Neurological Complications After Ischemic Stroke,UC-MSC infusion via intravenous route|UC-MSC infusion via intrathecal route|standard stroke treatment and rehabilitation therapy,Outcomes of Umbilical Cord Blood-derived Mesenchymal Stem Cell Infusion in Patients With Neurological Complications After Ischemic Stroke,Hanoi,,Vietnam,"July 15, 2021"
438,439,NCT04416139,Covid 19,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Infusion IV of Mesenchymal Stem cells,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study,Mexico City,,Mexico,"May 1, 2020"
439,440,NCT02644447,Premature Ovarian Failure,Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF,HUC-MSCs Transplantation|HUC-MSCs with Injectable Collagen Scaffold Transplantation,The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) With Injectable Collagen Scaffold Transplantation in Woman With Premature Ovarian Failure (POF),Nanjing,Jiangsu,China,October 2015
440,441,NCT01558908,Peripheral Vascular Diseases,Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia,Administration of ERC,"Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular",Indianapolis,Indiana,United States,May 2012
441,442,NCT03525418,HLHS,Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS),Longeveron Mesenchymal Stem Cells,Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS),Atlanta|Baltimore|Baltimore|Cincinnati|Salt Lake City,Georgia|Maryland|Maryland|Ohio|Utah,United States|United States|United States|United States|United States,"February 21, 2018"
442,443,NCT05338099,Duchenne Muscular Dystrophy,Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD),EN001|EN001,"Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)",Seoul,,"Korea, Republic of","January 18, 2022"
443,444,NCT05333406,"Charcot-Marie-Tooth Disease, Type IA",Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A,EN001|EN001,"Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A",Seoul,,"Korea, Republic of","February 22, 2022"
444,445,NCT03828344,Rheumatoid Arthritis,Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis,hUC-MSC suspension|Placebo,"A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Tolerability of a Single Intravenous Infusion of BX-U001, a Human Umbilical Cord Tissue Derived Mesenchymal Stem Cell Product, for Refractory Rheumatoid Arthritis",,,,July 2023
445,446,NCT05331872,Liver Cirrhosis,Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis,Human umbilical cord-derived mesenchymal stem cell infusion,"A Phase I, Open-label Trial on the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cell Administration in the Management of Adult Liver Cirrhosis",Hanoi,,Vietnam,"December 1, 2020"
446,447,NCT02037204,Foreign-Body Reaction|Inflammation|Effusion (L) Knee|Knee Pain Swelling,IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.,Cartilage repair surgery,Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.,Utrecht,,Netherlands,March 2013
447,448,NCT04482699,Severe COVID-19 Disease,RAPA-501-Allo Therapy of COVID-19-ARDS,RAPA-501-Allo off-the-shelf Therapy of COVID-19|Placebo,Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS,Hackensack,New Jersey,United States,"December 30, 2020"
448,449,NCT04520945,"Osteoarthritis, Knee",Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis,Chondrogen|Placebo,Phase 2B: Randomized Double-Blinded Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis,Cheras,Kuala Lumpur,Malaysia,"October 31, 2020"
449,450,NCT03629015,Stem Cells|Adult Stem Cells|Acute Liver Failure|Acute-On-Chronic Liver Failure|Steminent,Safety Study of Stemchymal® in Acute Liver Failure,Stemchymal®,"The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial",Taipei,,Taiwan,"October 1, 2018"
450,451,NCT02580695,Osteoarthritis,A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis,umbilical-cord mesenchymal stromal cells|Hyaluronic Acid,"A Phase I/II, Randomized, Double-blind, Controlled Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in Patients With Knee Osteoarthritis",Santiago,,Chile,December 2015
451,452,NCT05497401,Covid-related Pneumonia,A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With COVID-related Pneumonia,MesenCure|Placebo,A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With COVID-related Pneumonia,,,,October 2022
452,453,NCT05531266,aGVHD,Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease,hUC-MSCs|glucocorticoids,Clinical Study of Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease,Tianjin,Tianjin,China,"September 1, 2022"
453,454,NCT04234412,"Osteoarthritis, Knee",Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.,umbilical cord blood stem cell implantation for osteoarthritis treatment,Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.,,,,"February 1, 2020"
454,455,NCT03896568,IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma,MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma,Oncolytic Adenovirus Ad5-DNX-2401|Therapeutic Conventional Surgery,"Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma",Houston,Texas,United States,"February 12, 2019"
455,456,NCT03378063,Bronchopulmonary Dysplasia,Stem Cells for Bronchopulmonary Dysplasia,transplantation of mesenchymal stem cell|no transplantation of mesenchymal stem cell,Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study,Chongqing,Chongqing,China,"November 1, 2017"
456,457,NCT03257098,Skin Ulcer Venous Stasis Chronic,Allogeneic ABCB5-positive Stem Cells for Treatment of CVU,allo-APZ2-CVU,"An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)",Bochum|Erlangen|Greifswald|Hamburg|Kiel|Münster|Schwerin|Ulm|Würzburg,,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,"November 16, 2017"
457,458,NCT01460901,Neuroblastoma,"Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma",GD2 CAR modified Tri-virus specific cytotoxic t-cells,"Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to GD2 for Relapsed/Refractory Neuroblastoma Post-allo Stem Cell Transplantation With Submyeloblative Conditioning",Kansas City,Missouri,United States,October 2012
458,459,NCT04089579,Autism|Autism Spectrum Disorder,hCT-MSC in Children With Autism Spectrum Disorder,Cord Tissue Mesenchymal Stromal Cells|Placebo Infusion,"A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder",Durham,North Carolina,United States,"October 12, 2020"
459,460,NCT02407470,Severe Aplastic Anemia,Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia,Rabbit antithymoglobulin (ATG)|Adipose derived mesenchymal stem cells ( AD-MSCs)|AD-MSC transdifferentiated HSCs (AD-HSCs),"A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia",Beijing,Beijing,China,January 2015
460,461,NCT04313647,Healthy,A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers,1X level of MSCs-Exo|2X level of MSCs-Exo|4X level of MSCs-Exo|6X level of MSCs-Exo|8X level of MSCs-Exo,A Tolerance Clinical Study On Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers,Shanghai,Shanghai,China,"March 12, 2020"
461,462,NCT02543073,"Lung Diseases, Interstitial|Hematopoietic Stem Cell Transplantation|Bronchiolitis Obliterans",MSC for Treatment of Interstitial Lung Disease After Allo-HSCT,MSCs|AZM|Glucocorticoid,Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation,Guangzhou,Guangdong,China,September 2014
462,463,NCT04738981,Graft Vs Host Disease,Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT,UC-MSC|Anti-CD25 mAb,"Efficacy and Safety of UC-MSCS for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT: A Multicenter, Randomized, Open-label Trial",Beijing,Beijing,China,February 2021
463,464,NCT04399889,COVID|Corona Virus Infection|COVID19,hCT-MSCs for COVID19 ARDS,Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Placebo,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS),Boca Raton|Miami|Miami|Valhalla|Durham,Florida|Florida|Florida|New York|North Carolina,United States|United States|United States|United States|United States,"June 18, 2020"
464,465,NCT02580617,Crohn's Disease,A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease,ALLO-ASC,A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease,Seoul,,"Korea, Republic of",April 2015
465,466,NCT02923375,Graft vs Host Disease,A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease,Mesenchymoangioblast-derived mesenchymal stem cells,An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease,Sydney|Adelaide|Bristol|Leeds|Liverpool|Manchester|Nottingham,New South Wales|South Australia,Australia|Australia|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,"March 1, 2017"
466,467,NCT04173650,Dystrophic Epidermolysis Bullosa,MSC EVs in Dystrophic Epidermolysis Bullosa,AGLE 102,A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds,,,,October 2023
467,468,NCT03099239,Autism|Autism Spectrum Disorder|ASD,hCT-MSCs for Children With Autism Spectrum Disorder (ASD),hCT-MSC infusion,"A Phase I Study of hCT-MSC, An Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder",Durham,North Carolina,United States,"June 6, 2017"
468,469,NCT01733186,Degeneration Articular Cartilage Knee,"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",CARTISTEM®,"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee",Chicago|Chestnut Hill,Illinois|Massachusetts,United States|United States,"January 7, 2013"
469,470,NCT02394873,Burn,A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound,ALLO-ASC-DFU,A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Deep Second-degree Burn Wound,Seoul,,"Korea, Republic of",March 2015
470,471,NCT03339973,Peripheral Arterial Occlusive Disease,Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD,allo-APZ2-PAOD|Placebo,"A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)",Graz|Linz|Wien|Ústí Nad Labem|Berlin|Dresden|Freital|Hamburg|Hamburg|Heidelberg|Heidelberg|Karlsbad|Kiel|Mannheim|München|Trier|Poznań|Redhill,,Austria|Austria|Austria|Czechia|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Poland|United Kingdom,"March 5, 2018"
